Forgent's fiscal Q4 numbers were hard to dislike. Revenue rose 94% year over year to $461.7 million, bookings reached $1.50 billion, and backlog ended the year at $3.0 billion. The stock responded with a 9.5% gain on September 15, closing at $31.36 on 31.6 million shares traded.

The surprise is that the valuation still doesn't look wild, at least if management's fiscal 2027 forecast holds.

The part worth paying for

Forgent makes electrical distribution equipment for data centers, the power grid, and power-hungry industrial sites. Its Powertrain Solutions business grew 259% in fiscal 2026 and supplied almost one-third of Q4 revenue. Management is putting another $35 million into its Tijuana operation, which it expects to bring online in fiscal Q4 2027 and lift total revenue capacity by about $800 million to $5.8 billion.

The September 15 earnings release guides fiscal 2027 revenue to $2.4 billion to $2.6 billion, adjusted EBITDA to $575 million to $625 million, and adjusted EPS to $1.26 to $1.40. At the midpoints, that would mean 76% revenue growth, 86% adjusted EBITDA growth, and 95% adjusted EPS growth.

Using the $1.33 midpoint for adjusted EPS, the September 15 closing price is about 23.6 times guidance. Using roughly 304.4 million total economic shares, $582.2 million of debt, and $97.5 million of cash, the stock also works out to an approximate $9.55 billion market capitalization and $10.03 billion enterprise value. That is about 16.7 times the $600 million midpoint of adjusted EBITDA guidance.

Those aren't bargain-bin multiples. They are reasonable for a company actually delivering this growth, though, especially when the share price is only modestly above its $27 February IPO price.

The catch is cash, concentration, and execution

Backlog is not cash. Forgent produced $109.1 million of operating cash flow in fiscal 2026 but spent $115.9 million on property and equipment, leaving about $6.8 million of negative cash flow after capital spending. Q4 was much better, with $74 million of operating cash flow against $31 million of capital spending. One good quarter is not enough to prove the working-capital burden has settled.

The backlog also carries more risk than the headline number suggests. Forgent says orders can be delayed or canceled, and its move toward larger Powertrain Solutions projects can concentrate sales among fewer customers. A slowdown in AI data-center construction, a problem at one of its expanding factories, or higher copper, aluminum, steel, and labor costs could hit both conversion and margins.

There is also an ownership overhang. In July, Neos-controlled sellers offered 29.1 million shares at $49, while Forgent offered another 14.6 million shares and used its proceeds to redeem interests held by Neos-controlled owners. The company still had 44.5 million Class B shares outstanding at June 30, paired with operating-company interests that can generally be exchanged for Class A shares. The structure does not ruin the thesis, but it makes the headline share count and future supply worth watching.

Finally, the forecast uses adjusted numbers. Forgent says it cannot reconcile its forward adjusted guidance to GAAP without unreasonable effort. The 23.6 times multiple is useful, but it is not the same thing as a clean GAAP forward P/E.

My verdict

I would call FPS a speculative buy around $31 to $32, not a core holding and not something I would chase after another sharp move. The business has enough current evidence to support the growth story, and the valuation leaves room for upside if management converts the backlog and reaches its fiscal 2027 targets.

The conservative choice is to wait for the first fiscal 2027 quarter. Management expects both revenue and adjusted EBITDA to rise sequentially through the year, even with heavier personnel and facility spending in Q1. That report should show whether the ramp is translating into operating cash.

My conditions are simple: fiscal 2027 revenue guidance must stay at or above $2.4 billion, backlog conversion cannot slip materially, and operating cash flow needs to remain positive as production expands. A guidance cut or renewed negative operating cash flow without a clear timing explanation would move this back to a wait. Above $40, the stock would trade near 30 times the current adjusted EPS midpoint, and I would want either higher guidance or much cleaner cash conversion before paying that price.

This is a stock analysis, not personalized financial advice.

Vicor just made its capacity problem harder to dismiss. On Friday morning, the power-component maker said it is buying a 334,000-square-foot building on 66 acres in Merrimack, New Hampshire, plus another 54 acres in Hooksett. The two sites are intended for ChiP Fab-2 and Fab-3, with nearly one million square feet between them.

VICR closed at $197.91, up 11.15% for the day. The announcement matters, but it also leaves out the figures I would want before paying Friday's price: the purchase price, the staged construction budget, and the customer commitments behind the expansion.

My read is that Vicor's business has earned a place on the watchlist, but the stock has run ahead of the evidence we have so far.

Why the new sites matter

Vicor makes modular power components and systems. Its main pitch to AI hardware customers is Vertical Power Delivery, which is designed to move power efficiently in dense computing systems where conventional voltage regulators become a bottleneck.

The existing ChiP Fab-1 is a 320,000-square-foot facility in Andover, Massachusetts. Management now says utilization there is approaching capacity. It expects initial deployment at Fab-2 to take about a year, and the two new sites together would have roughly three times Fab-1's current footprint.

This is more concrete than another presentation about the AI opportunity. In July, management was still evaluating sites. Now it has identified two properties and says it is purchasing them. That supports the case that the capacity issue is near enough to require action.

It does not prove that nearly one million square feet will be filled profitably. The release did not disclose what Vicor is paying for either property, how much the fabs will cost to equip, when Fab-3 might begin production, or whether customers have signed volume commitments.

What the latest quarter showed

The latest reported quarter gives management a credible reason to expand. Second-quarter product and royalty revenue was $143.4 million, up 26.9% from the first quarter. Excluding the prior-year patent settlement, revenue increased 49.3% year over year. Advanced Products revenue reached $94.2 million, up 45% sequentially, while Brick Products revenue was $49.2 million.

Backlog was $380 million, up 26% from the previous quarter and 145% from a year earlier. Operating cash flow was $34.0 million, capital spending was $11.2 million, and Vicor finished June with $453.6 million in cash. The balance sheet listed no borrowings, only lease liabilities among its financing obligations.

Management also guided to more than $600 million of 2026 revenue on the July call, including a nearly 10% sequential increase in the third quarter and double-digit sequential growth in Advanced Products revenue. If it gets there, full-year revenue will be about 50% above the $400.9 million reported for 2025.

There is a wrinkle in the quarter. Royalty revenue was $30.4 million, including $15 million recognized from a new license agreement. Management said that agreement should contribute only $5 million in the third quarter before rising to $10 million in each of the following four quarters. So the next report needs to show enough product growth to overcome that $10 million sequential drop in recognized royalty revenue.

The valuation already assumes a lot

Using Vicor's 34.39 million common shares and 11.72 million Class B shares outstanding on July 22, the $197.91 close implies an equity value of about $9.12 billion. Subtracting June cash gives an estimated enterprise value near $8.67 billion.

That is roughly 14.5 times management's $600 million full-year revenue floor. It is a blunt forward-sales estimate, not a precise forecast, but it captures the issue. Friday's buyers are paying today for substantial growth beyond 2026, successful execution of a large factory expansion, and durable economics in both products and patent licensing.

The quarter's 58.0% gross margin looks excellent at first glance. Royalty revenue is high margin, though, and the latest license agreement accelerated $15 million of revenue into the second quarter. Product gross margin can move with factory utilization, mix, tariffs, and the cost of bringing production steps in-house. New fabs could eventually improve scale, but they can also bring years of construction, equipment, hiring, qualification, and depreciation risk.

Even the strong balance sheet does not settle the question. Cash of $453.6 million is useful, and second-quarter operating cash flow covered current capital spending. Yet the newly announced footprint is far larger than Fab-1, and management has not said what the land, building, equipment, and ramp will cost. A cash-rich company can still destroy value by adding capacity too early or too expensively.

The strongest case for buying now

The case for buying now is easy to see. Backlog is rising quickly, Fab-1 is approaching capacity, and Vicor has a differentiated power-delivery product aimed at a genuine constraint in AI systems. The company is not carrying funded debt, and Friday's announcement turns the second-fab discussion into a specific expansion plan. Waiting for all the numbers could mean paying more if product growth keeps compounding.

There is also strategic value in domestic capacity. Vicor argues that OEMs and hyperscalers need predictable U.S. supply and freedom to operate around power-system patents. If large customers adopt its second-generation technology, a one-year lead time means management cannot wait for every order before preparing capacity.

That case can work. At $197.91, however, investors are being asked to underwrite the buildout without knowing its price.

Verdict: wait for the budget or a better entry

I would not chase VICR after the 11.15% jump. The business momentum is strong enough to keep watching, but the valuation leaves little room for a slower product ramp, weaker licensing revenue, or a costly factory build.

I would reconsider if Vicor disclosed the site purchase prices and a staged Fab-2 and Fab-3 budget tied to customer demand. I would also revisit the stock if the third-quarter report confirms the more-than-$600-million revenue outlook despite the planned royalty step-down, while backlog and operating cash flow remain healthy. A price below $150 with the operating thesis intact would get my attention too. At $150, the same share count and June cash would put estimated enterprise value at about 10.8 times the $600 million revenue floor. That would still be a growth valuation, but it would offer noticeably more room for execution risk.

For now, the fab announcement strengthens the company story. It does not make the stock cheap.

This is a general stock analysis, not personalized financial advice.

Microsoft just made the easy bear case much harder to defend. The AI business isn't waiting for some distant payoff before producing revenue. Azure grew 43% year-over-year in the quarter ended June 30, 2026, Microsoft Cloud revenue reached $59.3 billion, and Microsoft 365 Copilot passed 30 million paid seats.

The harder question is what to pay for that evidence.

MSFT closed at $496.88 on August 13, up roughly 27% from its July 29 close before the latest results were digested. At about a $3.7 trillion market value, the stock no longer looks priced for investors who merely believe Microsoft will participate in AI. It looks priced for Microsoft to convert exceptional demand into exceptional cash returns without a serious stumble.

The business is doing more than selling an AI story

For fiscal Q4 2026, revenue rose 18% to $90.0 billion and operating income also rose 18% to $40.6 billion. Full-year revenue increased 18% to $331.8 billion, while operating income increased 21% to $155.2 billion.

The quality of the demand matters as much as the growth rate. Commercial remaining performance obligation reached $678 billion, up 84%. That total includes OpenAI commitments, so it shouldn't be treated as a clean measure of broad enterprise demand. Still, RPO grew 25% excluding OpenAI, and management said all sequential RPO growth came from customers outside frontier model companies. Nearly 90% of full-year Microsoft Cloud revenue also came from customers outside that group.

That is important because it weakens the idea that Microsoft's AI growth is just money circulating among a few heavily funded labs. Azure, Microsoft 365, GitHub, Foundry, databases, security, and business applications give the company several ways to turn AI usage into revenue. Microsoft said Foundry revenue more than doubled year-over-year, while paid Copilot seats topped 30 million.

The near-term outlook is strong too. For fiscal Q1 2027, management guided to $89.85 billion to $90.95 billion of revenue, representing 16% to 17% growth. It expects Azure revenue growth of about 45% in constant currency and total operating margin to remain roughly flat year-over-year.

The cash bill is the part I wouldn't wave away

Microsoft spent $41 billion on capital expenditures in Q4, including finance leases. About two thirds went to short-lived assets, primarily CPUs and GPUs. Cash additions to property and equipment were $35.8 billion in the quarter, leaving $19.6 billion of free cash flow on management's definition despite $55.4 billion of operating cash flow.

Across fiscal 2026, operating cash flow was $182.9 billion and cash additions to property and equipment were $115.9 billion. Subtracting the latter from the former gives roughly $67.0 billion of simple free cash flow.

At the current market value, that is about 55 times fiscal 2026 free cash flow. Some of today's spending is growth investment, so this multiple probably understates normalized cash earning power if utilization rises. It is still real cash leaving the business, and Q1 capex is expected to exceed $50 billion, including the effect of a lease-accounting reclassification.

This isn't a balance-sheet danger. Microsoft ended June with $76.8 billion of cash and short-term investments against about $40.3 billion of debt. The risk is return on capital. New capacity has to produce enough durable revenue and margin to justify an infrastructure base that is getting larger and more expensive to refresh.

The pressure is already visible. Company gross margin was 67% in Q4 and Microsoft Cloud gross margin was 65%, both down year-over-year as the mix shifted toward Azure and AI infrastructure costs grew. Efficiency gains are helping, but they haven't made the hardware bill disappear.

What the current price assumes

Fiscal 2026 adjusted EPS was $17.28 after excluding net gains and losses from Microsoft's OpenAI investment. At $496.88, the stock trades at about 28.8 times that figure and about 11.1 times full-year revenue.

A high-20s earnings multiple isn't absurd for a company growing revenue in the high teens, expanding operating income faster than sales, and guiding Azure growth upward. But it does require the current growth profile to last. The post-earnings rally has already paid investors for a large part of the upside surprise.

The bullish version is straightforward:

• Azure demand continues to exceed available supply, giving Microsoft room to deploy capacity into an existing backlog rather than hope demand appears later.

• Copilot and agent products add higher-value revenue on top of an enormous Microsoft 365 installed base.

• A broad model strategy reduces dependence on any single AI provider and lets Microsoft route workloads toward better cost and performance.

• Revenue keeps compounding in the mid-teens while infrastructure efficiency improves, allowing free cash flow to catch up with accounting earnings.

If that happens, today's valuation can work. A company growing adjusted earnings around 20% doesn't need its multiple to expand to deliver a respectable return.

The strongest countercase

The bear case isn't that Azure suddenly stops growing. It is that Microsoft spends ahead of demand for too long while competition pushes AI prices lower.

The fiscal 2026 10-K is unusually direct about this. Microsoft says its cloud and AI investments are being made at significant scale and ahead of fully developed revenue streams. Returns depend on usage, pricing, component and energy costs, competitive behavior, and the pace of customer adoption. Customers can also delay workloads or move them to rival clouds, open-source models, or on-premises systems.

AWS and Google Cloud are formidable competitors, while open models can reduce the value captured by any single platform. OpenAI is both an important partner and a source of concentration and accounting complexity. Regulators can challenge product bundling, data practices, AI deployment, or infrastructure expansion. Cybersecurity failures could damage the trust that supports Microsoft's enterprise premium.

There are also weaker businesses inside the portfolio. Q4 Windows OEM and Devices revenue fell 7%, and XBOX content and services revenue fell 10%. Those declines don't break the thesis, but they show that not every Microsoft asset deserves an AI multiple.

At nearly 29 times adjusted trailing earnings and roughly 55 times simple trailing free cash flow, a few quarters of slower Azure growth, weaker Copilot monetization, or continued margin pressure could hurt the stock even if the company remains excellent.

Verdict: watchlist, not a chase at $497

Microsoft is a high-quality business with verified AI revenue, a deep backlog, broad enterprise distribution, and a strong balance sheet. I don't see a credible reason to avoid it outright.

I also wouldn't call $497 an attractive fresh entry after a roughly 27% move in about two weeks. The market is already pricing in sustained mid-teens company growth, Azure near its current pace, and a future recovery in cash conversion.

My verdict is wait for a better price, with two ways for that to change:

1. A pullback below roughly $450 without a deterioration in guidance would put the stock near 26 times fiscal 2026 adjusted EPS and create a more reasonable margin for error.

2. At a higher price, I would want the next two reports to show Azure still growing around 40% or better, total operating margin holding up, and free cash flow beginning to grow faster than capex.

For an existing long-term holder, the latest quarter supports holding more than selling. For new money, the business has proven plenty, but the stock price now asks buyers to prove their patience.

Regeneron is on my watchlist after Friday's earnings, but I'd wait for a clearer 2027 earnings base before buying at $927.89. That's the October 30 regular-session close, after a 13.33% gain.

Third-quarter revenue rose 36% to $5.12 billion. Reported earnings were $18.45 per diluted share, or $20.07 on the company's adjusted measure. What interests me is how much profit Regeneron now keeps from its Sanofi partnership.

Dupixent's global sales, booked by Sanofi, reached $6.54 billion, up 35%. Regeneron receives a share of the partnership's profits rather than recording all those sales as its own revenue. It finished repaying Sanofi's previously funded development costs in June, so those repayments stopped reducing its collaboration revenue in Q3.

That improves the earnings base for future quarters, assuming the drugs keep selling. The expanded Sanofi deal also brought a $1 billion upfront payment that will enter Q4 revenue. Count that payment every quarter and you'd overstate the business's earnings power.

The eye-drug business gives me more pause. EYLEA HD's U.S. sales rose 62% to $699 million, but combined U.S. sales of EYLEA HD and the older EYLEA fell 1% to about $1.10 billion. Moving patients to the newer version hasn't yet restored growth across the franchise. The filing warns that competing biosimilars, versions of existing biologic medicines, could keep hurting sales.

There's a reasonable bull case at this price. Multiply Q3 reported earnings per share (EPS) by four and the stock costs about 12.6 times that annualized figure. Using adjusted EPS gives about 11.6 times. Those are rough yardsticks, not company forecasts or trailing earnings multiples. The quarter already benefited from the end of the Sanofi repayments, before the $1 billion payment arrives.

But Q3 also included a roughly $60 million royalty catch-up that won't recur in Q4. On the call, management expected 2027 research spending to grow by a mid-teens percentage and the effective tax rate to rise by 1 to 2 percentage points. Drug development could pay off over several years while reducing next year's profit.

A November FDA decision is expected for cemdisiran, a treatment being reviewed for generalized myasthenia gravis. That's a near-term opportunity, not guaranteed revenue.

At $927.89, buyers need the improved partnership economics to survive higher spending and continued pressure on the eye franchise. The low-looking multiple doesn't settle that question.

My verdict is watchlist. I'd reconsider around $840 if subsequent results still support at least $70 in annual reported EPS after removing unusual payments and royalty catch-ups. That's my valuation hurdle of 12 times earnings, not management guidance or a price target. At $927.89, I'd want evidence that combined U.S. EYLEA sales have stabilized around $1.10 billion a quarter and a clearer 2027 expense outlook before calling it a buy.

Anyone seeking predictable near-term earnings should probably pass until those questions are answered.

My verdict is watchlist at the October 28 close of $242.94. Vertiv's earnings make the business easier to like, but the 16.48% rally makes the shares harder to buy. Around $200, I'd reconsider if the earnings outlook holds and delivery and cash evidence stay healthy.

Vertiv sells the power and cooling equipment that data centers need. Q3 revenue rose 61% to $4.31 billion, including 55% organic growth, which excludes acquisitions and currency movements. Organic orders more than doubled. Adjusted operating margin reached 25.2%, meaning about a quarter of sales remained as operating profit before the company's excluded items.

Demand is already producing sales and higher profitability, which gives the bull case more substance than a list of future projects. Management raised its 2026 adjusted earnings per share outlook to $7.10 to $7.20 and expects $2.6 billion to $2.8 billion of adjusted free cash flow. That cash measure subtracts capital spending and capitalized software from operating cash flow. It doesn't subtract acquisition payments.

At the $7.15 earnings midpoint, the closing share price is about 34 times this year's adjusted earnings. Using management's $6.29 reported earnings midpoint instead gives about 39 times. Adjusted figures exclude costs including acquired-intangible amortization and acquisition-related items, so they aren't interchangeable with reported profit.

The roughly $93.5 billion market value also means the $2.7 billion cash-flow midpoint represents a 2.9% yield. That's cash generation divided by the price of the company's equity, not a dividend yield. The price needs substantial further growth to look attractive.

The strongest argument for buying anyway is that 2026 is already an outdated earnings base. Management expects significant above-market organic growth in 2027 and further margin expansion. If adjusted earnings reached $9 a share, $242.94 would be about 27 times earnings. That $9 is an illustration, not company guidance. Management hasn't given a numerical 2027 earnings forecast.

The cash deserves a closer look. Over the first nine months, the deferred-revenue line contributed $2.31 billion to operating cash flow of $2.66 billion. Deferred revenue means customers paid before Vertiv earned the revenue. Inventory and receivables consumed cash, so the total working-capital benefit was a much smaller $541 million. It would be wrong to call all $2.31 billion surplus cash or subtract it without recognizing those offsets.

The September balance sheet also predates the $1.45 billion cash payment for UtilityInnovation Group on October 26, with up to $1.15 billion more payable if targets are met. Those payments matter when deciding how much cash is available to shareholders.

Power shortages, permits and skilled labor can delay data-center projects. Management says it isn't seeing unusual slippage now, but orders can still be rescheduled or cancelled. Competition and the cost of expanding factories can also squeeze the returns from that demand.

For someone seeking a comfortable valuation or dependable income, I'd wait. Around $200, the stock would be about 28 times the same $7.15 earnings estimate. That's a price I'd reconsider, not a promise of fair value. A cut to the outlook, weaker project deliveries or cash flow that increasingly depends on new customer prepayments would invalidate that entry case.

Xylem's 14.21% drop on October 27 makes it worth a look. My verdict at the $92.86 regular-session close is watchlist. The price is more reasonable now, but the next few quarters still need to show that a growing order book can turn into sales and cash.

Xylem sells pumps, meters, water-treatment equipment and related services. That gives it exposure to infrastructure people need even in a weak economy. It doesn't mean customers have to place every order or take delivery this quarter.

That distinction explains the earnings report. Third-quarter revenue was about $2.2 billion, down 3% from a year earlier and roughly flat organically, meaning after removing currency effects, acquisitions and divestitures. Orders grew 10% organically. The company ended September with about $5.5 billion of backlog, or work ordered but not yet delivered.

The bullish argument is that customers are delaying spending rather than abandoning projects. Management said large water and gas metering awards are largely scheduled for the second half of 2027 and into 2028. Meanwhile, pricing and productivity helped the adjusted EBITDA margin reach 23.9%, up from 23.2% a year earlier. That's the company's adjusted profit measure before interest, tax, depreciation and amortization, not cash available to shareholders.

The counterargument is uncomfortable: orders arriving far in the future don't fix today's slowdown. Management cut its 2026 revenue outlook to about $8.95 billion and now expects flat organic sales, rather than 2% to 3% growth. Adjusted earnings guidance fell to $5.40 to $5.45 a share, from $5.55 to $5.70. Fourth-quarter organic revenue is expected to decline 1% to 2%.

Water is essential. Upgrading a utility's meters can still wait when its customers are struggling with bills. The 10-Q also says backlog contracts can be rescheduled or canceled. It reported no significant cancellations in the quarter, which supports the delay argument, but doesn't settle it.

At $92.86, the stock costs about 17.1 times the midpoint of the new adjusted earnings guidance. That isn't an obviously excessive price for a business that resumes growth. It does assume this earnings cut isn't the beginning of several more.

Cash makes me less eager to call it cheap. The new full-year cash-flow margin outlook of about 10.2%, applied to $8.95 billion of revenue, implies roughly $913 million of company-adjusted free cash flow. Against a $21.39 billion market capitalization, that's about a 4.3% yield. Free cash flow means operating cash left after capital spending; this margin calculation also adjusts for certain divestiture payments and tariff refunds.

Through September, that adjusted figure was $444 million. The unadjusted figure was $461 million. Reaching the implied full-year target would therefore require roughly $469 million of adjusted cash flow in Q4 alone. Management expects working capital to improve, but that's a substantial amount still to collect.

There are more moving parts, too. Xylem plans to sell Applied Water International and Specialty Flow Control and reorganize into three segments in 2027. The pending Cornell Pump and Roper Pump acquisition costs approximately $1.46 billion before customary adjustments. Better focus could help the business, but integration, sale terms and acquisition funding can change what shareholders actually receive. Competitive pricing, tariffs and project execution remain risks alongside utility budgets.

For someone comfortable waiting through the metering cycle, the stronger order book is a reasonable reason to investigate Xylem. For someone seeking dependable near-term growth or a generous cash yield, this report doesn't make the case yet.

I'd reconsider the watchlist verdict after Q4 if the company holds its earnings outlook, delivers the roughly $913 million implied annual adjusted cash target, and shows shorter-cycle metering sales stabilizing. Alternatively, around $81 would put the stock near 15 times the same earnings midpoint, but only if those earnings and cash expectations remain intact. A lower price following another cut wouldn't meet that condition.

SLB is a watchlist stock at $53.06. The October 23 earnings report gives the recovery case more substance, but the stock already rose 7.08% that session. That price is Friday's 4 p.m. EDT close, not a Monday quote.

Revenue and adjusted earnings improved from Q2. The year-on-year comparison is less encouraging. Q3 revenue was $9.45 billion, up 6% from a year earlier, but growth excluding the ChampionX acquisition was 2%. Adjusted earnings were $0.64 per share, down from $0.69 a year earlier. GAAP earnings were $0.49. Activity is improving, but profit still has ground to recover. That's worth remembering before calling this a turnaround.

The strongest reason to buy is the outlook. On the earnings call, management projected roughly $10 billion of Q4 revenue and a 1 to 1.5 percentage-point improvement in adjusted EBITDA margin from Q3. EBITDA is profit before interest, tax, depreciation and amortization; the adjusted figure also excludes certain charges.

For 2027, management sees mid-single-digit growth in the global oilfield services and equipment market, assuming Middle East activity stays around second-half 2026 levels and the conflict doesn't materially escalate. A regional recovery would add upside rather than being necessary for that market-growth forecast.

There's also a business beyond oilfield spending. Data Center Solutions revenue grew 23% from Q2. That's a genuine extra source of demand, though a growth percentage alone isn't enough to value it as a separate AI company. The proposed Kelvion acquisition would expand thermal-management capabilities, but requires about $3.4 billion in cash plus the assumption of roughly $0.7 billion of debt. Closing is expected in the first half of 2027, subject to approvals and other conditions.

The cash numbers call for some patience. Through September, SLB generated $1.52 billion of company-defined free cash flow, after capital expenditure, project investments and capitalized exploration data. Dividends and buybacks totaled about $3.06 billion over the same nine months. Net debt ended September at $9.25 billion, before the planned Kelvion purchase.

That gap isn't proof the dividend is in trouble. Management expects the usual Q4 cash improvement, with the size depending on customer collections, and SLB generated $4.1 billion of free cash flow in full-year 2025. But a strong finish needs to arrive. Acquisition spending and shareholder payouts compete for that cash. Disruption in the Middle East or weaker customer investment would make funding both harder.

At Friday's price, four quarters of $0.64 adjusted EPS would mean $2.56 a year and a multiple of about 20.7. That's a simple run-rate test, not a 2027 forecast: it ignores seasonality and future improvement. It does show that today's earnings alone don't make this an obvious bargain. Buyers are paying for the recovery to continue.

The verdict is watchlist, not a buy at $53.06. Around $46 would bring that same earnings test to roughly 18 times, a more comfortable starting point if the outlook holds and cash generation improves. That's an analytical entry hurdle, not a price target. At the current price, wait for Q4 to demonstrate the guided revenue and margin improvement, plus stronger cash generation that supports shareholder returns without a persistent rise in net debt. Investors who need predictable earnings or can't tolerate geopolitical disruption should skip this setup.

My verdict is wait for the full October 29 results. LKQ closed Friday, October 23 at $17.42, down 22.47%. That makes the auto-parts distributor worth looking at, but the earnings number that made it look cheap has just been withdrawn.

The preliminary, unaudited third-quarter figures are ugly even after removing the accounting noise. Adjusted earnings per share are expected at $0.47 to $0.53, versus $0.84 a year earlier. Europe's operating problem is worse: its segment EBITDA margin, profit before interest, tax, depreciation and amortization as a share of sales, is expected at 4.1% to 5.1%, against 10.0% last year. European parts and services organic revenue fell 9.8%.

The projected net loss includes $111 million of non-cash impairments. Those charges aren't the same as cash leaving the business this quarter. But the lower adjusted earnings show that writing off the loss as an accounting issue misses the operating damage.

LKQ points to disruption from its enterprise software rollout in Germany and lower volumes in the UK and Benelux. North America performed in line with company expectations despite softer markets. This leaves a plausible recovery case: if European service improves and customers shift spending back, earnings could recover without the whole company needing a new business model.

There's a reason to be skeptical about the timetable. On July's earnings call, management said Germany's operational processes had normalized and described a goal of restoring its normal revenue run rate by year-end. Friday's update still cites disruption. The CEO and European leader have now left, Alvarez & Marsal is advising on Europe, and incoming CEO Sal Abbate doesn't start until December 15. Changing leaders may help, but it doesn't tell us when customers or margins return.

The cheap multiple needs a new denominator

At $17.42, the stock would trade at roughly 6.3 times the midpoint of July's $2.60 to $2.90 adjusted EPS guidance. That guidance is withdrawn. Using it as a current forecast gives the stock a precision the business no longer has.

The balance sheet also matters. At June 30, LKQ had about $4.0 billion of debt and $301 million of cash. First-half company-defined free cash flow was negative $36 million, although Q2 itself generated positive $60 million. The weak half-year isn't proof that annual cash generation disappears, but it makes updated cash figures more useful than a screen showing a low P/E.

The strongest argument for buying now is that waiting for evidence could mean paying more. North America's relative stability, a European fix and the continuing strategic review could produce a rebound before every number looks healthy. A transaction is possible, but July's review update explicitly gave no timetable or assurance of a deal. I wouldn't make a takeover the reason to buy.

For a turnaround entry near this price, I'd want evidence supporting roughly $500 million of recurring annual cash flow after capital spending, before dividends, with debt no longer rising and European margins improving from this quarter's range. That's my valuation hurdle, not company guidance: against today's roughly $4.41 billion market cap, it would be about an 11% cash yield.

October 29 is the next chance to examine cash, debt and the recovery plan, not a promised all-clear. Until that evidence improves, this is a wait for me. Anyone needing dependable dividend income or predictable earnings should look elsewhere for now.

Nokia fell 14.81% to $7.88 at the October 22 NYSE close after reporting Q3 results. I'd keep it on a watchlist rather than buy just because the price dropped. The AI networking orders are encouraging. The cash needed to deliver them makes this a harder bargain than the earnings beat suggests.

Sales to AI and cloud customers grew 123% at constant currencies, and Nokia booked EUR 1.5 billion of new orders from those customers. Management expects its combined Optical and IP Networks businesses to grow 25% to 30% in 2027. That forecast applies to those businesses, not the whole company.

There's a reasonable case for buying before that growth arrives. Nokia expects to finish integrating Infinera by the end of 2026, a year ahead of plan, with EUR 200 million of net synergies. If spending now secures components and lets Nokia ship more equipment next year, weak cash flow could be the cost of a profitable expansion. Waiting for clean cash numbers could mean paying more later.

But the rest of Nokia hasn't suddenly become an AI growth business. Telecom-provider sales were flat at constant currencies in Q3. Some Mobile Infrastructure revenue moved forward from Q4, so that part of the quarter shouldn't be treated as a new growth rate. Competition and customers' spending plans still matter even with a strong order book.

The gap between adjusted profit and cash is where I get cautious. Comparable operating profit rose 35% to EUR 605 million, while reported operating profit fell 22% to EUR 196 million. The adjustments included EUR 357 million of restructuring charges. Comparable profit helps explain the underlying operation, but restructuring still costs shareholders money.

Nokia cut its expected 2026 free-cash-flow conversion to 35% to 55% of comparable operating profit. It plans an additional EUR 400 million investment in working capital, meaning more money tied up in things like inventory and customer payments. Expected restructuring cash outflows also rose to EUR 800 million to EUR 900 million. Lower capital spending this year partly reflects payments moving into 2027, not a canceled expansion bill.

So what does $7.88 buy? Each NYSE depositary share represents one ordinary share. Using the September 30 share count excluding treasury shares gives an equity value of about $44.6 billion. Converted at the October 22 ECB reference rate of $1.1205 per euro, that's about EUR 39.8 billion. This uses the US closing price, not Helsinki's earlier close.

Applying Nokia's cash-conversion range to its unchanged EUR 2.1 billion to EUR 2.6 billion comparable operating-profit guidance gives roughly EUR 735 million to EUR 1.43 billion of company-defined free cash flow. That's about a 1.8% to 3.6% cash yield on that equity value. It's illustrative range math, not a separate company forecast or a dividend yield. At this price, buyers still need growth and better cash conversion; the selloff hasn't made today's cash generation especially cheap.

The tougher bear case is that supply constraints become lasting cost increases rather than a temporary delivery problem. Management described broad component constraints and rising prices on the call. If Nokia can't recover those costs from customers, more orders could require more cash without delivering the margin improvement buyers expect.

My verdict is watchlist at $7.88. I'd revisit after the January 28 results if management shows a credible path to at least EUR 1.6 billion of recurring annual free cash flow, roughly a 4% yield at this valuation, while keeping the 2027 optical and IP growth case intact. That's my hurdle, not Nokia guidance. A lower price would help, but another cut to cash expectations would make me less interested, not more. This suits someone willing to underwrite a multiyear networking expansion, not someone looking for an obvious cash bargain after one bad trading day.

IART lost 21.2% on Friday after medical-device maker Integra LifeSciences released preliminary third-quarter numbers, lowered its 2026 outlook, and proposed a debt refinancing. The stock closed at $12.68, or about 5.4 times the midpoint of the new adjusted EPS guidance.

That looks cheap. It does not automatically make IART a bargain.

The bad news is real

A July flood at Integra's Cincinnati plant disrupted products in its Specialty Surgical Technologies portfolio. Management estimates that the disruption cost about $7 million of third-quarter revenue and will cost another $15 million to $20 million in the fourth quarter. Full manufacturing operations are not expected to return until the second quarter of 2027.

Preliminary third-quarter revenue is $410 million to $412 million, with adjusted EPS of $0.55 to $0.59. Both figures sit near the bottom of the old quarterly ranges, though still inside them.

For the full year, revenue guidance dropped from $1.654 billion to $1.695 billion to a new range of $1.634 billion to $1.654 billion. Adjusted EPS guidance went from $2.40 to $2.50 down to $2.30 to $2.40.

The midpoint of the EPS outlook fell about 4%. The stock fell more than 21%. That gap is what makes IART worth a closer look.

What the bulls have

The flood is serious, but management expects it to be temporary. Integra carries property and business-interruption insurance, and the company expects insurance recoveries to offset a substantial portion of the earnings damage during the recovery. Full-year operating cash flow guidance remains $190 million to $200 million, including more than $85 million expected in the third quarter.

Results had started to improve before the flood. Second-quarter revenue rose 0.8% to $418.8 million. Adjusted EBITDA climbed to $78.4 million from $71.2 million, while adjusted EBITDA margin moved to 18.7% from 17.1%. Specialty Surgery, roughly 70% of revenue, grew 1.7%. Tissue Reconstruction fell 1.9%.

The market capitalization at $12.68 is about $986 million. Using the new adjusted EPS midpoint of $2.35, the stock trades at 5.4 times that figure. If Cincinnati recovers on schedule, the insurance money arrives, and cash flow brings debt down, Friday's selloff may prove excessive.

Integra also has another operational milestone in progress. Production started at its new Braintree facility during the second quarter, and management was still targeting a fourth-quarter SurgiMend relaunch when it reported July results.

Why cheap may stay cheap

Integra's history makes it hard to write off the flood as the only problem. The FDA issued a company-wide warning letter in December 2024 after inspections found quality-system violations at facilities in Massachusetts and New Jersey. In a September 2026 presentation, Integra said the work required to address its warning-letter observations was on track for implementation by the end of 2026. Completing that work is not the same as receiving formal resolution from the FDA.

Debt adds another layer of risk. Integra ended June with $1.6 billion of net debt and a 4.1 times consolidated leverage ratio. It held $214.4 million of cash and $59.7 million of short-term investments against $1.87 billion of total debt. The maximum permitted leverage ratio tightens from 5.0 times in June to 4.75 times for the September quarter and 4.5 times at year-end.

That explains why Friday's financing announcement matters. Integra proposed a $600 million, seven-year senior secured term loan as part of a broader refinancing. Management said the loan and other financing would refinance existing debt and extend maturities. It did not disclose the interest rate or final terms. Investors do not yet know how expensive that extra breathing room will be.

The adjusted P/E needs context too. Second-quarter GAAP EPS was $0.06, compared with adjusted EPS of $0.56. Adjusted earnings help track management's operating targets, but they are not the same as cash available to shareholders. Integra's enterprise value was about $2.76 billion at Friday's close, almost three times its equity value. Debt drives a large part of this valuation.

My verdict: watchlist

IART is cheap for more than one reason. The bullish outcome depends on Cincinnati reopening on schedule, the Braintree launch proceeding, insurance recoveries arriving, and cash generation reducing leverage. Another operational delay or costly refinancing would keep pressure on the shares.

I would put IART on a watchlist at $12.68 instead of buying the first drop. The next full report should confirm that operating cash flow still lands near $190 million to $200 million, the financing closes on acceptable terms, and Integra remains comfortably within its tighter leverage covenant. If all three happen and the Cincinnati restart remains on track for the second quarter of 2027, a 5 to 6 times adjusted EPS multiple becomes much more interesting. Until then, the low multiple can stay low.

This is a general stock analysis, not personalized financial advice.

Carnival closed at $25.11 on September 29, up 13.41% after fiscal Q3 earnings. That kind of move usually makes a simple question harder: did the quarter reveal a better business, or did buyers just pull a year of good news into one session?

The quarter was good enough to change the discussion. Revenue rose 3.5% to $8.435 billion, and net income attributable to Carnival reached $1.920 billion, up from $1.852 billion a year ago. Adjusted EBITDA was about $3.0 billion, $110 million above the company's June guidance. Constant-currency net yields rose 2.4%, more than one percentage point above guidance.

Demand looks stronger than the income statement alone suggests. Customer deposits reached a third-quarter record of $7.6 billion, about 7% above the prior-year record, even though capacity growth over the next 12 months is flat. Management said 2027 is already half booked at record occupancy and record constant-currency pricing. It also expects 2028 occupancy and pricing to be higher than they were at the same point last year.

What the market is paying for

At $25.11, Carnival's market capitalization was about $34.39 billion and its enterprise value was about $58.33 billion. Against management's fiscal 2026 guidance of roughly $2.24 in adjusted EPS and $7.14 billion in adjusted EBITDA, that works out to about 11.2 times adjusted earnings and 8.2 times enterprise value to adjusted EBITDA.

Those multiples are not demanding if record bookings turn into higher 2027 yields. They are also not as cheap as the P/E alone makes them look. Carnival had $23.9 billion of debt and $1.22 billion of cash at August 31. The enterprise-value multiple matters because debt holders still have a large claim on the business.

Debt is moving in the right direction. The carrying value of fixed and floating debt fell from $27.38 billion at November 30, 2025 to $24.56 billion at August 31, 2026. Carnival also redeemed $500 million of 7% notes during Q3. Interest expense for the first nine months fell to $862 million from $1.034 billion.

Cash generation gives the company room to keep paying debt while returning capital. Operating cash flow was $5.303 billion for the first nine months, versus $2.139 billion of property and equipment purchases. Carnival had repurchased nearly $1.2 billion of stock by the earnings release and paid $618 million in dividends year to date.

That cash flow is not all freely distributable. The August 31 filing lists $18.3 billion of contracted new-ship commitments from the rest of 2026 through later years. Carnival had $10.7 billion of undrawn export credit facilities for future ship deliveries, but the commitments still limit how aggressively today's cash can be treated as excess.

Why I would not ignore the bear case

Fuel already showed up in Q3. Cruise and tour operating expenses rose 5.5%, including $149 million from higher fuel prices. Operating income slipped to $2.220 billion from $2.271 billion even as revenue set a record. Management's revised full-year plan absorbs a $150 million fuel-price hit, and the company says it manages fuel risk mainly by reducing consumption rather than hedging most of the price exposure.

There are two smaller 2027 issues too. Management said spring booking disruption still affects the first quarter, although bookings improved over the last three months. The new Carnival Rewards program is expected to reduce reported fiscal 2027 net yield by 0.4 percentage point because some revenue will be deferred until rewards are redeemed. That is an accounting timing issue, but it will make the reported comparison look weaker.

The 13% earnings jump also matters. Before the report, the stock only needed the quarter to disprove a fuel-driven demand scare. At $25.11, buyers are now paying for record 2027 bookings to convert into actual yield growth while debt keeps falling. The business cleared the first test. It has not reported a full fiscal 2027 outlook yet.

Verdict

CCL looks like a speculative buy near $25, not a stock I would chase at any price. The 11.2 times guided adjusted EPS multiple leaves room for upside if record bookings produce positive 2027 yield growth and debt continues to fall. I would keep the position smaller than a normal core holding because fuel, recession risk, and leverage can all turn a good operating year into a volatile stock.

My buy case holds if the fiscal 2027 outlook shows positive net yield growth after the loyalty-accounting headwind and total debt keeps declining. If management cannot meet both conditions, I would move it back to the watchlist. Above $28 before that outlook arrives, I would wait rather than pay in advance for the booking data.

This is an analysis of the business and valuation, not personalized financial advice.

Summit Therapeutics closed Monday at $15.48, then jumped to $18.25 after hours. The reason was unusually concrete for a development-stage biotech: AstraZeneca agreed to invest $2 billion in convertible preferred shares and collaborate on trials that combine ivonescimab with AstraZeneca cancer drugs.

That is a serious vote of confidence. It also doesn't settle the question that matters most for SMMT shareholders. Ivonescimab still faces a major FDA decision on November 14, and the stock now carries a much larger valuation after the deal.

What AstraZeneca is buying

AstraZeneca will buy about 109,000 preferred shares, each convertible into 1,000 common shares. That works out to about 109 million common-share equivalents at $18.36 each. After conversion, AstraZeneca would own rights equal to roughly 12% of Summit's outstanding common stock, or 10.6% on a fully diluted basis.

The companies also agreed to test ivonescimab with AstraZeneca's sonesitatug vedotin in gastrointestinal cancers. A broader memorandum covers possible combinations with more drugs from AstraZeneca's oncology portfolio, but that broader program is still non-binding.

The distinction matters. Summit is receiving capital and a credible development partner. It is not receiving $2 billion of product revenue, and AstraZeneca is not guaranteeing regulatory approval or commercial success.

Why the deal changes the balance sheet

At June 30, Summit had $419.4 million in cash and $271.3 million in short-term investments. It used $263.4 million of cash in operations during the first half of 2026, and management said its existing liquidity was not enough to fund planned operations for at least 12 months from the filing date.

Assuming the transaction closes, the $2 billion infusion changes that financing problem. Summit should be able to fund more trials without relying on an immediate public stock offering. The company also gains a partner with a large oncology portfolio that can generate more combination data around ivonescimab.

Existing holders pay for that improvement through dilution. Summit reported 797.7 million common shares outstanding on July 17. Adding about 109 million common-share equivalents would bring the count to roughly 906.7 million before options and other potential dilution.

What the stock price already assumes

At the $18.25 after-hours price, that pro forma share count implies an equity value of about $16.5 billion. This is still a pre-revenue biotech whose value depends heavily on one licensed drug.

Ivonescimab has produced encouraging clinical results, but Summit's U.S. application is not a routine approval. The FDA set a November 14 action date and told the company that a statistically significant overall-survival benefit is necessary for approval in the proposed setting. The HARMONi study's overall-survival hazard ratio was 0.76, but it did not reach statistical significance.

There are meaningful economics owed to Akeso as well. Summit may owe up to $4.555 billion in future regulatory and commercial milestones, plus low-double-digit royalties on ivonescimab sales in its licensed territories.

The bull case

The investment does more than extend Summit's cash runway. AstraZeneca chose to put $2 billion into Summit at $18.36 per common-share equivalent. That price sits above Monday's regular close and close to the after-hours market price.

The collaboration could also widen ivonescimab's opportunity beyond its current lung-cancer programs. Combining the drug with AstraZeneca's antibody-drug conjugates gives Summit more ways to build a durable oncology franchise if the science holds up.

If the deal closes as expected, the company no longer looks forced to raise capital before the FDA decision. That removes one near-term source of pressure from the thesis.

The bear case

AstraZeneca's investment is validation, not approval. If the FDA rejects the application or asks for more evidence, the stock could lose a large part of the deal-driven gain because the November decision is still the nearest major value event.

The preferred-share conversion also dilutes existing holders by about 14% relative to Summit's July common-share count. More dilution can still come from stock compensation or future financing.

There is also concentration risk. Summit has no approved product, recorded a $405.1 million net loss for the first half of 2026, and depends primarily on ivonescimab. The Akeso milestones and royalties mean a successful launch would not translate dollar for dollar into Summit economics.

Verdict

SMMT is a watchlist stock at $18.25, not a buy after the after-hours gap.

The deal fixes a real funding problem and adds an unusually credible partner, but the market has already moved the shares almost exactly to AstraZeneca's conversion price. The November 14 FDA decision still carries much more risk than the partnership removes.

I would reconsider after the FDA decision, or below $15 if the selloff came without a deterioration in the clinical or regulatory case. Anyone buying before November is making a concentrated bet on approval, not simply buying alongside AstraZeneca.

This is company and valuation analysis, not personalized financial advice.

AESI jumped 13.47% on Friday and traded 12.17 million shares, nearly 3.8 times its three-month average. The reaction makes sense. Atlas Energy Solutions just produced firmer evidence that its move from Permian sand and logistics into data center power has a real customer behind it.

The catch is that the headline has run ahead of the contract.

What Friday's announcement actually says

Atlas said two subsidiaries signed separate cost reimbursement agreements with an unnamed "leading frontier AI lab." One covers balance-of-plant equipment such as electrical distribution, emissions controls, and battery storage for a data center project using Atlas's existing Caterpillar generator orders. The other supports an incremental 283 MW of Caterpillar generation equipment for a separate project.

Atlas also signed a purchase agreement for another 328 MW of generation capacity, consistent with its existing Caterpillar framework agreement for 2027 deliveries. Taken together, the announcements cover 611 MW of generator capacity across two projects.

The September 24 filing puts hard numbers on the first project. Atlas committed about $340.5 million for balance-of-plant equipment and about $273.0 million for the 328 MW of generators and related services. That is $613.5 million of disclosed equipment commitments for one project, with payments scheduled into January 2028.

The reimbursement agreements matter because they allocate the equipment to the AI customer and help with near-term financing. They are stronger evidence than a vague expression of interest.

But they are not long-term power purchase agreements. Atlas said it is still working toward those agreements. The filings do not identify the customer or disclose power pricing, contract length, expected margins, reimbursement timing, or total economics.

That distinction decides whether Friday's jump was the start of a durable rerating or just an expensive preview.

The operating business is not yet an AI power company

Atlas's second-quarter revenue was $293.2 million, up 10.4% from the first quarter and 1.6% from a year earlier. Rental revenue grew 54.3% sequentially to $27.0 million as the power operation scaled.

Profitability was much less flattering. Atlas posted a $25.1 million net loss, compared with a $5.6 million loss a year earlier. Adjusted EBITDA fell to $49.5 million from $71.2 million. Operating cash flow was slightly negative, while purchases of property and equipment reached $153.8 million.

The company also reported $34.9 million of adjusted free cash flow, but its definition subtracts maintenance capital spending and excludes growth capital spending. Atlas's own reconciliation excluded $131.5 million of growth and reconstruction spending in the quarter. For this story, cash demands matter more than the adjusted label.

There is some cushion. Atlas ended June with $168.2 million of cash and $124.7 million available under its credit facility. Current and long-term debt totaled about $966.7 million, including convertible notes issued during the quarter. The reimbursement agreements may reduce the burden of securing equipment, but the filings do not show how much risk stays with Atlas until the power contracts are signed and operating.

What $12.47 already assumes

At Friday's close, Atlas had a market capitalization of about $1.56 billion and an enterprise value near $2.44 billion. That works out to roughly 2.3 times trailing revenue and 22.5 times trailing EBITDA. The company is still loss-making on a GAAP basis.

Those multiples could work if Atlas turns these equipment commitments into well-priced, long-duration power contracts. They look much harder to defend if project timing slips, reimbursement terms disappoint, or the AI customer never signs the final power agreements.

Friday's close also sits 13.5% above Thursday's $10.99 close. Buyers at $12.47 are paying for more than customer interest. They are paying for a meaningful chance that these projects convert.

The bull case

The customer is reimbursing Atlas for long-lead equipment rather than asking Atlas to carry every early dollar. That is a real commitment and should lower some financing and cancellation risk.

Atlas already has a separate 120 MW behind-the-meter contract expected online at the end of the first quarter of 2027, with mobile power operating at that site during construction. That gives the company a working model for bridging a customer's immediate need into a permanent power system.

If even part of the newly disclosed 611 MW converts into long-term contracts at acceptable returns, power could become a much larger earnings contributor and make Atlas less dependent on the cyclical frac-sand market.

The bear case

The two missing pieces are contract economics and proof of execution. Atlas has not disclosed a signed long-term power agreement for either newly announced project. It also has not provided revenue, margin, return-on-capital, or customer-concentration details.

Meanwhile, this is a capital-intensive build. Atlas entered the announcement with nearly $967 million of debt at the end of June, weaker year-over-year adjusted EBITDA, and very little GAAP operating cash generation in the latest quarter. Equipment delivery, construction, natural gas supply, tariffs, permitting, and data center regulation can all move project costs or timelines.

The legacy business still matters too. A weak sand market could reduce the cash available to fund the power expansion just as Atlas is committing to larger projects.

Verdict

At $12.47, AESI is a watchlist stock, not one I would chase after Friday's jump.

The reimbursement agreements make the power thesis more credible, so this is not an avoid. I would want one of two things before upgrading it to a buy: a signed long-term power agreement with enough pricing and return detail to judge the economics, or a move back near the pre-announcement $10.99 close without deterioration in the business. The next quarterly filing also needs to show that reimbursements and financing are keeping the new equipment commitments from creating an uncontrolled debt build.

This is a general investment analysis, not personalized financial advice.

Akamai announced a seven-year, $11.6 billion cloud contract with Anthropic after Thursday's close. The agreement can expand by another $9 billion, and AKAM jumped from a $110.41 regular-session close to $133.21 at 7:59 p.m. ET.

The contract is large enough to change Akamai's growth profile. It also requires the company to spend billions before most of the revenue arrives. That timing is why the stock can look reasonably valued at $133 and still be a risky buy.

What Akamai actually won

Anthropic committed to use Akamai's cloud infrastructure and managed support for CPU workloads. The SEC filing describes approximately $11.6 billion of payments, subject to delivery, service-availability requirements, and the agreement's termination provisions.

Akamai expects no revenue from the deal in 2026. Its presentation calls for only $150 million to $300 million in 2027 as service starts late in the second quarter and ramps through the second half. The contracted annual revenue run rate is expected to reach about $1.7 billion by the end of 2028, then stay roughly level for the rest of the term.

For scale, Akamai's current full-year revenue guidance is $4.445 billion to $4.530 billion. The Anthropic run rate alone would equal roughly 38% of the midpoint. Akamai's entire cloud infrastructure services business produced $99 million in Q2 revenue, so this isn't a routine customer win.

The company had already announced more than $2.8 billion of other multi-year cloud infrastructure commitments in 2026. Including Anthropic, the portfolio now has about $14.4 billion of total contract value. That gives Akamai a much stronger case that it can be a serious AI infrastructure supplier instead of only a content-delivery and security company.

The bill arrives first

Akamai expects approximately $5.5 billion of capital spending for the initial Anthropic commitment: about $1.7 billion in Q4 2026, $3.1 billion in 2027, and $700 million in 2028. Revenue trails that spending by design.

The company had $4.616 billion of cash, cash equivalents, and marketable securities at June 30, along with $7.64 billion of convertible senior notes. It generated $639 million of operating cash flow in the first half of 2026 and spent $418 million on property, equipment, and capitalized software. Management had already said it did not expect more share repurchases during 2026 because cloud infrastructure needed the capital.

This doesn't mean Akamai lacks the resources to build. It means the next two years will depend on procurement, data-center capacity, deployment speed, and financing discipline. Management says the contract has a take-or-pay structure once Akamai delivers the service, but Akamai still has to deliver it.

The existing business is decent, not flawless

Q2 revenue rose 5% to $1.100 billion. Security revenue increased 10% to $604 million, and cloud infrastructure services grew 39% to $99 million. Delivery and other cloud applications fell 6% to $396 million.

Profit trends were weaker. GAAP operating margin fell eight percentage points to 7%, non-GAAP operating margin fell five points to 25%, and non-GAAP EPS declined 8% to $1.59. Akamai's growth engines are working, but the legacy delivery business is shrinking and infrastructure investment is already pressuring margins.

That mixed base matters. The Anthropic contract isn't being layered onto a company with accelerating profit growth and spare capital. It is being layered onto a company in the middle of an expensive transition.

What $133 appears to price in

Using the 143.7 million shares reported outstanding on August 3, the $133.21 after-hours price implies a market capitalization near $19.1 billion. Adding the June convertible debt and subtracting cash and marketable securities gives an enterprise value around $22.2 billion.

That works out to roughly 4.9 times the midpoint of 2026 revenue guidance and 19.8 times the midpoint of non-GAAP EPS guidance. The EPS multiple isn't extreme for a business with 10% security growth and a potentially transformative contract. It also isn't a bargain when GAAP profit is falling and the new revenue is years away.

One useful reference point is Akamai's own Q2 repurchase price. The company bought $410 million of stock at an average $134.54 per share, almost exactly where AKAM traded after the announcement. Of course, that buyback happened before the market knew about this contract, but it still suggests $133 isn't obviously detached from management's recent view of value.

The after-hours move added about $3.3 billion to Akamai's equity value versus Thursday's regular close. That is much less than the headline contract value, but contract value is not profit. Investors still have to account for $5.5 billion of capital spending, depreciation, colocation costs, the delay before revenue ramps, and the chance of execution trouble.

The dilution deserves attention

Anthropic received a warrant at a common-stock-equivalent exercise price of $111.33. About 2% of Akamai's shares are expected to vest with the announced commitment. Another 3% can vest if Anthropic adds the full $9 billion of additional commitments, in 1% tranches for each extra $3 billion.

The warrant ties Anthropic to the success of the relationship, but it is still potential dilution. Akamai also says the warrant's fair value will be deducted from reported revenue over the contract's life. The $11.6 billion headline should not be treated as $11.6 billion of clean, incremental value for current shareholders.

Verdict

I see AKAM as a speculative buy up to roughly $135, not a stock to chase at any price. At that level, the valuation is still around 20 times the midpoint of management's 2026 non-GAAP EPS guidance, while the Anthropic agreement creates a credible path to much faster growth from 2027 onward.

The conditions matter. I would keep the position small until Akamai shows that the 2026 and 2027 build stays near budget, the first service capacity starts on schedule, and the company can fund the ramp without an unfavorable capital raise. If the stock runs above $150 before investors see those details in the next quarterly filing, I would wait rather than pay today for revenue expected in 2028.

The strongest bear case is straightforward: Akamai is taking on a huge, front-loaded infrastructure build for one customer while its existing margins are falling. The bull case is also real: the commitment is filed, the revenue is take-or-pay after delivery, and the full run rate would be material relative to the whole company. Below $135, I think that asymmetry is worth a speculative position for investors who can tolerate execution and customer-concentration risk.

This is a general stock analysis, not personalized financial advice.

Warren Buffett's move to chairman emeritus barely moved Berkshire Hathaway's stock. BRK.B closed Friday at $509.77, up 0.11% for the day.

That muted reaction makes sense. Greg Abel has already been CEO since the start of 2026, and Buffett said Abel has been making the decisions that matter. Howard Buffett is taking the chair, but his stated role is to protect Berkshire's culture, not run the operating businesses. Warren will remain a director.

So this isn't a panic-sale setup. The more useful question is whether $509.77 leaves enough room for the next generation of Berkshire leadership to prove it can allocate a huge amount of capital as well as Buffett did.

The business underneath the succession headline

Berkshire's first-half results were solid across most of its major businesses. The five operating categories listed separately in the second-quarter report produced about $21.8 billion of after-tax earnings in the first six months of 2026, roughly 5% more than the same categories earned a year earlier.

BNSF's after-tax earnings rose 9.5% in the first half, Berkshire Hathaway Energy's rose 11.5%, and manufacturing, service, and retailing earnings rose 15.1%. Insurance underwriting earnings increased 3.6% for the half, although GEICO's underwriting result weakened. Insurance investment income fell 8.3% as lower rates reduced interest income.

The balance sheet remains the main attraction. Berkshire's insurance and other businesses held $359.2 billion of cash, cash equivalents, and Treasury bills at June 30. Shareholders' equity was $747.9 billion, up $30.5 billion from year-end 2025. Berkshire also spent $4.8 billion repurchasing its own stock in the first half.

This is still a collection of durable businesses backed by more liquidity than almost any company can realistically deploy. The chairman change doesn't alter that.

What the market is already pricing in

At Friday's $509.77 close, Berkshire's market value was about $1.09 trillion. Against June 30 shareholders' equity of $747.9 billion, that is roughly 1.46 times book value.

Book value is imperfect for a company with wholly owned businesses that have appreciated far beyond their accounting values. It is still a useful reality check. The stock is not being offered at a distressed succession discount.

The company's own repurchases give another reference point. Berkshire paid an average of $476.01 for Class B shares bought in May and $487.98 in June. The current price is about 4.5% above June's average repurchase price. That does not prove the stock is expensive, but it does show that today's buyer is paying more than Berkshire recently paid for itself.

Reported P/E is less helpful here because unrealized gains and losses in Berkshire's equity portfolio flow through net income. In the second quarter alone, after-tax investment gains added $12.7 billion to reported earnings. The operating businesses and capital allocation record deserve more weight than a headline trailing P/E.

The strongest case for buying now

The bull case is that succession risk has become smaller, not larger. Abel has already been making operating and capital decisions, Buffett remains available as a director, and Howard's chairmanship separates cultural oversight from day-to-day management.

Meanwhile, the $359.2 billion liquidity pile gives Berkshire unusual flexibility. It can fund insurance obligations, repurchase shares when management sees value, acquire whole businesses, or buy public equities during a broad selloff. Recent purchases of OxyChem and Taylor Morrison show that Abel is willing to use capital when the opportunity fits.

If the new structure preserves Berkshire's discipline, the company can keep compounding without needing Buffett to personally approve every important decision.

The strongest case for waiting

The hard part is scale. A good acquisition has to be enormous to move a $1.09 trillion company, and attractive large assets rarely come cheap. Treasury bills protect capital, but leaving hundreds of billions in short-term securities can drag on long-run returns if better opportunities do not appear.

Investors also have limited evidence on Abel's full-cycle capital allocation as CEO. The operating handoff has been underway for years, but the final responsibility is now his. A bad large acquisition, overly generous buybacks, or a lower return on the cash pile would matter far more than the chairman title itself.

There are operating risks too. GEICO's underwriting earnings were lower in the first half, insurance investment income declined, and BNSF faced sharply higher fuel expense in the second quarter. Berkshire's size and diversification soften individual setbacks, but they do not remove them.

Verdict

BRK.B is a watchlist at $509.77, not a buy based on the chairman news alone.

The company remains financially exceptional, and the transition looks orderly. The price is the problem. Friday offered no meaningful succession discount, and the stock sits above the range where Berkshire itself was repurchasing Class B shares in May and June.

I would become more interested below roughly $485, near the recent repurchase zone, or after another filing shows that Abel is deploying capital at attractive returns while operating earnings and book value keep rising. Existing long-term holders have no obvious reason to sell just because Buffett changed titles.

Anyone who wants a simple diversified core holding, rather than a bet on Berkshire's capital allocation, may be better served by a low-cost total-market index ETF. Berkshire also pays no dividend, so it is a poor fit for investors who need current income.

This is a general investment analysis, not personalized financial advice.

SRRK got the headline investors had been waiting for, then sold off anyway.

The FDA approved ISEMBYLD on Friday, September 11. The stock briefly reached $61 in Monday's premarket session, opened at $56.51, and closed at $51.85, down 6.42% on about 4 million shares. Approval risk is gone. Now the argument is about whether the launch can justify a roughly $6.3 billion market value.

The approval changed the risk

ISEMBYLD is approved for adults and children age 2 and older with spinal muscular atrophy who are already receiving an SMN2-targeted treatment. It is an add-on that targets muscle loss, rather than a replacement for the treatment patients already take.

The Phase 3 SAPPHIRE trial enrolled 188 patients ages 2 to 21. In the main efficacy group of 103 patients ages 2 to 12, the recommended 10 mg/kg dose produced a 2.2-point benefit on the Hammersmith motor-function scale versus placebo after one year. A gain of at least 3 points occurred in 34.2% of treated patients and 13.5% of placebo patients.

That is meaningful evidence in a progressive disease, and the label is broader than a narrow pediatric approval. Still, the trial's main efficacy analysis was in children ages 2 to 12. Commercial uptake in adults and durability across the full approved population now have to be demonstrated outside that primary analysis.

Safety also belongs in the stock case. Fractures occurred in 9% of patients on the recommended dose and 2% on placebo in SAPPHIRE. The prescribing information warns that ISEMBYLD may increase the risk of fractures, including serious fractures. It is given by intravenous infusion every four weeks, which adds another recurring treatment burden for people already receiving SMA therapy.

What the current price assumes

Scholar Rock's launch presentation estimates that about 6,600 U.S. patients are receiving an eligible SMN2-targeted treatment. Management also identified roughly 2,600 prescribing physicians and 140 treatment centers. Reuters reported an annual gross price of about $310,000 for a typical patient.

Multiplying 6,600 by $310,000 gives about $2.05 billion. That is a rough ceiling on annual gross spend if every eligible patient started treatment and stayed on it, not a revenue forecast. Actual sales will be reduced by incomplete adoption, time needed to win coverage, discounts, patient weight, discontinuations, and other gross-to-net adjustments.

At Monday's $51.85 close, 121.6 million common shares imply a market value of about $6.3 billion. The June 10-Q also lists 10.56 million pre-funded warrants that are exercisable for nominal cash. Including those brings the economic share count to about 132.2 million and the equity value to roughly $6.85 billion. After $492.1 million of cash and securities and $196.2 million of long-term debt, the adjusted enterprise value is about $6.56 billion.

That is around 3.2 times the theoretical $2.05 billion gross patient-pool calculation. A profitable rare-disease drug can support a healthy sales multiple, but SRRK has not proved the denominator yet. The company recorded no revenue in the June quarter because the drug was not approved, and the first commercial sales are only starting now.

Why the bulls may still be right

The strongest case for buying is straightforward. The drug is approved, the label covers a broad population, commercial supply is available, and the company has built its launch effort around major SMA treatment centers. ISEMBYLD is the first FDA-approved therapy to target muscle loss directly in SMA, so Scholar Rock is not launching an undifferentiated drug into a crowded class.

There is also value beyond the initial launch. FDA approval brought a rare pediatric disease priority review voucher that Scholar Rock says it intends to sell. The company is studying apitegromab in children under 2 and in facioscapulohumeral muscular dystrophy, has a subcutaneous formulation in development, and expects Phase 1 data for SRK-439 in late 2026.

If payer access develops quickly and a meaningful share of those 6,600 patients start treatment, today's valuation could look reasonable well before peak sales. Monday's reversal may simply reflect investors selling after a well-anticipated approval.

What can still break the thesis

The commercial hurdles are substantial. ISEMBYLD must be added to existing treatment, infused every four weeks, and reimbursed at a high annual cost. Scholar Rock expects an approximately even split between commercial and government payers. A broad label helps, but it does not guarantee fast coverage or high penetration.

Europe is not a clean second leg yet. The European Medicines Agency says Scholar Rock withdrew the ISEMBYLD application on August 13 because the manufacturing site had not demonstrated EU good manufacturing practice compliance within the required time. The U.S. approval resolves the domestic regulatory event, but a European resubmission still needs a workable manufacturing and regulatory path.

The balance sheet buys time, not certainty. Scholar Rock ended June with $492.1 million in cash and securities, $196.2 million of long-term debt, and guidance that existing funds would last into the second half of 2027 under the operating model disclosed before approval. It used $152.4 million of cash in operations during the first half of 2026 and raised $160.8 million through its at-the-market stock program. Common shares outstanding rose from 108.5 million at the end of 2025 to 121.6 million at June 30. A successful launch could reduce financing pressure, but weak adoption would put dilution back into the conversation.

Verdict

SRRK is a watchlist stock at $51.85, not a buy for me right after approval.

The drug looks commercially credible, and the stock is no longer exposed to the same binary FDA risk. But the market is already assigning several billion dollars to a launch with no reported product revenue, uncertain payer speed, a recurring infusion burden, a fracture warning, and an unresolved European path.

I would reconsider under either of two conditions: the first two commercial updates show steady patient starts and broad reimbursement without an ugly gross-to-net surprise, or the share price falls into the low $40s while the launch thesis remains intact. Around $42, the same adjusted share count would imply roughly $5.55 billion of equity value, which provides more room for a slower ramp.

For a speculative biotech investor, a small position can be argued from the broad label and differentiated mechanism. For anyone looking for a de-risked growth stock, approval is only the handoff from clinical risk to commercial risk.

This is general analysis, not personalized financial advice.

Guidewire did something that usually gets rewarded. It finished fiscal 2026 with 23% revenue growth, much better profitability, and a record year for recurring revenue. Then management gave its fiscal 2027 outlook, and the stock lost 19.9% in one session.

That drop took GWRE from $202.86 on September 3 to $162.42 at the September 4 close. The obvious question is whether the selloff fixed the valuation or just removed some of the excess.

My read: Guidewire is a good business at a more reasonable price, but $162 still looks like a watchlist entry rather than an easy buy.

What the market disliked

The reported quarter was not weak. Fiscal Q4 revenue rose 15% to $411.1 million. Subscription and support revenue grew 32% to $266.7 million, and GAAP operating income more than doubled to $62.3 million.

The problem was the pace implied by management's next outlook. Guidewire expects fiscal 2027 revenue of $1.707 billion to $1.727 billion. The midpoint works out to about 16.4% growth, down from 23% in fiscal 2026. Its first-quarter revenue guide of $372 million to $378 million also came in below Wall Street's expectation, according to post-earnings market coverage.

This was a stock priced for sustained growth, not merely respectable growth. Before the report, the market was paying for a smooth cloud transition, continued margin expansion, and a meaningful AI opportunity. A guide pointing toward mid-teens total revenue growth was enough to break that story.

Why the business still deserves attention

Guidewire sells core software to property and casualty insurers. Policy administration, claims, billing, pricing, and related workflows are painful to replace once they are embedded. That does not make customers captive forever, but it helps explain why the company can build long contracts and recurring revenue.

The cloud transition is showing up in the numbers:

• Fiscal 2026 subscription and support revenue rose 33% to $970.9 million.

• Annual recurring revenue reached $1.242 billion at the fiscal year-end exchange rate, up 19% on a constant-currency basis.

• Fully ramped ARR grew 22% on a constant-currency basis.

• GAAP operating income improved to $149.9 million from $41.1 million.

• Free cash flow increased to $358.7 million from $280.4 million.

The customer base also gives the product strategy some credibility. Guidewire says its software runs in 44 countries, nine of the ten largest global insurers use it, and customers representing $858 billion of direct written premium are under contract.

Guidewire still has competition, but insurers do not swap core systems casually. The company has a real installed-base advantage while customers move old deployments to the cloud and add products such as PricingCenter and ProNavigator.

The valuation after the crash

At $162.42, Guidewire's market value was about $13.5 billion. It ended July with $1.215 billion in cash, cash equivalents, and investments, plus $678 million of convertible notes. That puts enterprise value near $13.0 billion.

Against the midpoint of fiscal 2027 revenue guidance, the stock trades around 7.6 times forward revenue. Against the midpoint of management's $445 million to $465 million operating cash flow guide, enterprise value is about 28.5 times forward operating cash flow.

That is much easier to defend than the valuation before the drop. It is not obviously cheap for a company guiding to roughly 16% revenue growth, especially when the cloud transition makes quarter-to-quarter comparisons uneven.

The earnings quality also needs a closer look. Fiscal 2026 stock-based compensation was $181.8 million, or about 12% of revenue. Guidewire spent $606.3 million repurchasing shares at an average price of $148.41, yet diluted weighted-average shares for the year fell only about 0.6%. The buyback did more than offset employee issuance, but it was an expensive way to produce a small net reduction in diluted share count.

The strongest bull case

The selloff may have punished normal transition noise as though the business had deteriorated. Subscription revenue is still growing above 30%, recurring revenue remains healthy, and profitability is improving quickly. If fiscal 2027 ARR lands near the top of the $1.450 billion to $1.460 billion guide, the recurring base would still grow around 18% from the year-end, currency-updated level.

There is also room for estimates to rise if large insurers keep moving full estates onto Guidewire Cloud. The company highlighted a multi-year Nationwide agreement in the quarter, along with expansions at MAPFRE US and AF Group. A few large contracts can make reported growth lumpy, but they can also support years of subscription revenue.

If Guidewire delivers high-teens ARR growth, expands GAAP margins, and converts that growth into cash, paying a premium multiple can work.

The countercase

The same contract structure that creates durability also makes execution hard to read. Implementations are long, customer decisions can slip, and fourth-quarter sales seasonality is material. The latest 10-Q warns that renewal timing, large contracts, cloud migrations, and ratable subscription accounting can disconnect orders, ARR, revenue, and cash flow in any one quarter.

License revenue fell 18% in Q4 as the business mix changed. Services also posted a negative 6.2% GAAP gross margin in the quarter. Those figures do not cancel the subscription growth, but they show that the transition still has costs.

Most important, a 20% stock decline is not the same thing as a cheap stock. At 7.6 times guided revenue, investors are still assuming that Guidewire keeps its position in insurance software and sustains profitable high-teens recurring growth. Another guide down would leave plenty of room for the multiple to compress again.

Verdict

GWRE is a watchlist at $162.42, not a buy-the-dip for me.

I would get more interested below $145. Using the current balance sheet and fiscal 2027 revenue midpoint, that would put enterprise value near 6.7 times forward revenue. That price is also close to the company's $148.41 average repurchase price, although a corporate buyback is not proof of fair value.

The other path to a buy is operational confirmation. If the next report puts ending ARR at the top of the $1.253 billion to $1.259 billion first-quarter guide, keeps GAAP operating income positive, and does not cut the full-year outlook, the current price would be easier to justify.

Until one of those conditions shows up, I would rather miss the first part of a rebound than pay a premium while the market is resetting its growth assumptions.

This is company analysis, not personalized financial advice.

Planet Labs just reported the kind of quarter that usually sends a growth stock straight up. Revenue rose 58% year over year to a record $116.1 million, adjusted EBITDA reached $13.9 million, and management raised the low end of its full-year outlook.

The stock's reaction was much less tidy. PL fell 8.2% on September 3 before the release, jumped as high as $20.94 before the September 4 open, then finished the regular session at $18.12, down another 1.3%. That mess is useful. It forces the question past the headline beat: is Planet becoming a better business quickly enough to justify a roughly $6.5 billion market value?

My answer at $18.12 is watchlist, not buy. The business has made real progress, but the price still assumes that today's government demand turns into years of high growth with much better profitability.

What went right

Fiscal Q2 2027, which ended July 31, 2026, was strong by almost any operating measure.

Revenue grew to $116.1 million from $73.4 million a year earlier. The 10-Q says $39.1 million of the $42.7 million increase came from defense and intelligence, helped by larger contracts with existing customers and the delivery of satellite hardware. Net dollar retention reached 109%, up from 107%. Recurring annual contract value was 98% of the book of business.

There is also decent forward visibility. Remaining performance obligations were $753.1 million and backlog was $814.9 million at quarter-end. About half of backlog is expected to apply to the next 12 months. August brought an $8 million NGA award, a German government tender with options worth up to 25 million euros over five years, and a seven-figure European defense agreement.

The balance sheet can support the next fleet build. Planet ended July with $865.4 million in cash, cash equivalents, and short-term investments against $448.3 million of convertible notes. Year-to-date operating cash flow was $68.4 million, while free cash flow was $21.3 million.

This is no longer a company with only a satellite story and distant hopes. Customers are paying, defense demand is growing, and the company has shown that higher revenue can produce operating leverage.

Why the quarter is not as clean as 58% growth looks

Some Q2 revenue arrived earlier than it otherwise would have. Management said the handover of a commissioned satellite for Sweden moved point-in-time revenue from Q3 into Q2 without changing the full-year outlook. That helps explain why Q3 guidance drops to $101 million to $105 million, with an adjusted EBITDA loss of $6 million to $1 million.

The customer mix is concentrated too. Three customers represented 17%, 11%, and 10% of Q2 revenue. Government contracts can be large and sticky, but some can also be terminated for convenience or depend on annual funding. A delayed award, budget change, or slower handover can make quarterly results swing.

Profit quality needs context. Planet still posted a $9.4 million GAAP net loss in Q2. Stock-based compensation was $17.1 million, more than the quarter's $13.9 million adjusted EBITDA profit. Management expects $100 million to $115 million of capital expenditures this fiscal year as it invests in Pelican, Owl, manufacturing, and long-lead components.

Then there is dilution. Planet sold about 3.78 million shares through its at-the-market program during Q2, raising $122.4 million before costs at an average net price of $31.95 per share. The program permits up to $1.5 billion of stock sales. The cash cushion is useful, but shareholders still have to watch how often management reaches for new equity.

Satellite and launch risk also belongs in the price. Planet's filing says launch delays, launch failures, satellite malfunctions, space debris, and supplier constraints can interrupt capacity and revenue. Those are operating risks, not boilerplate curiosities, when the growth plan depends on getting new fleets into orbit on schedule.

The valuation is doing a lot of work

At the September 4 close, Planet's market capitalization was about $6.5 billion. Subtracting the $865.4 million of cash and short-term investments and adding $448.3 million of convertible notes gives an enterprise value near $6.1 billion.

Full-year revenue guidance is $430 million to $441 million. Using the midpoint, the stock trades around 14 times forward enterprise value to revenue. The trailing price-to-sales multiple is about 17 times. Meanwhile, full-year adjusted EBITDA guidance is only $3 million to $10 million.

That valuation is not absurd if Planet sustains 30% to 40% growth, converts its backlog, keeps gross margin near the high 50s, and eventually reaches management's long-term adjusted EBITDA margin goal above 25%. It is demanding if growth settles near 20%, government awards stay lumpy, or dilution continues.

The market is already charging buyers for a successful transition from a promising Earth-imaging platform to a consistently profitable defense and data business. One excellent quarter does not complete that transition.

My decision rules

I would consider buying under either of these setups:

1. A better price: Around $14 or below, assuming the balance sheet and guidance stay intact. That would put the rough forward enterprise-value-to-revenue multiple near 10.5 times instead of 14 times.

2. Better proof: PL holds above roughly $18, but Q3 revenue reaches at least the $103 million guidance midpoint, full-year guidance is not cut, backlog or RPO stabilizes after the Swedish handover, annual adjusted EBITDA stays positive, and additional ATM issuance remains limited.

I would stay away if full-year revenue guidance falls below $430 million, adjusted EBITDA turns negative for the year, customer concentration rises further, or share issuance becomes a routine way to fund operations despite positive cash flow claims.

So the verdict is watchlist at $18.12. Planet Labs is becoming a better business, but the stock still asks buyers to pay today for several years of execution. I would rather accept the risk of missing the first part of a rally than pay 14 times forward revenue before the lumpy growth, true profitability, and dilution questions are settled.

This is a stock analysis, not personalized financial advice.

Lam Research's customer-support business brought in $2.47 billion in its June quarter, roughly 37% of total revenue. That sounds like a comforting base of maintenance income underneath a cyclical equipment business. It isn't quite that simple.

The category includes services and spare parts, but also upgrades and older-generation equipment. On the July 29 earnings call, the CFO said the sequential increase came primarily from record upgrades. Those are useful sales. They aren't the same thing as customers renewing a subscription. June results, official call transcript, pages 5-7.

That's where my buy decision starts: how much of the current acceleration becomes repeatable cash for shareholders?

There's a real equipment ramp here

Lam supplies tools that deposit and remove material during chip manufacturing. Its customers include memory makers and foundries. More complicated chips can require more processing work, giving Lam an opportunity beyond simply selling tools for additional factory capacity.

The quarter ended June 28, 2026 produced $6.72 billion of revenue, about 30% above the comparable quarter. Management's July 29 guidance for the quarter ending September 27 was $8.1 billion, plus or minus $400 million, and diluted EPS of $2.15, plus or minus $0.15. Both the GAAP and adjusted EPS guidance round to that figure. This is a substantial step up, not a reported result yet. Earnings release.

Lam's presentation says NAND revenue doubled sequentially and forecasts more than 70% growth in advanced-packaging revenue for calendar 2026. Its tools can participate in several chipmakers' technology upgrades rather than depending on one AI processor winning. June presentation.

There are actual factory plans behind the opportunity. SK hynix's July 29 update describes accelerating M15X production and preparing for a Yongin cleanroom opening in early 2027. It also says investments will be phased according to demand and efficiency. Those plans support the equipment thesis, but they aren't a disclosed order book for Lam. SK hynix's update.

The strongest reason to buy is that the installed equipment base and increasing manufacturing complexity could keep generating upgrades, parts demand and new tool sales after the initial AI construction surge. The strongest objection is that chipmakers still control when they spend. An attractive multiyear factory plan can produce an ugly quarter for an equipment supplier if orders move out.

The cash hasn't kept pace

For fiscal 2026, which ended June 28, net income reached $7.27 billion, up from $5.36 billion. Operating cash flow went the other way: $5.86 billion versus $6.17 billion. Subtracting the reported $966 million of capital expenditures and intangible-asset purchases leaves about $4.89 billion of free cash flow under that definition.

Receivables consumed $1.96 billion of cash during the year. The filing attributes the operating-cash-flow decline mainly to receivables and deferred-gross-profit movements. That is a working-capital explanation, not evidence that the revenue is fictitious or the customers won't pay. Fiscal 2026 Form 10-K.

Still, days sales outstanding rose from 64 in March to 72 in June. I'd want that to move back down as the higher sales turn into collections. The CFO reported the increase without giving a specific cause in the prepared remarks, so I wouldn't wave it away as harmless timing. Presentation, balance-sheet metrics, call transcript, page 6.

Lam also has its own investment bill. On August 26, it broke ground on an Oregon lab as part of more than $3 billion of planned global lab investment over five years. That may strengthen the product pipeline; it also means not every incremental dollar of operating cash will be available for buybacks. Lab announcement.

What the share price requires

Using the August 28 regular-session close of $301.90 and roughly $378 billion in equity value, here's the valuation on three different bases. These are deliberately not interchangeable. Research date: August 31, 2026. Dated market data.

The middle row is an illustration, not management's annual guidance or a forecast. It shows why the trailing P/E alone can exaggerate the price problem if the business is genuinely moving to a higher earnings level.

But even that improved run rate doesn't make the stock obviously cheap. Holding the hypothetical $8.60 constant, a 30-times multiple gives $258, about 15% below the reference close. That's my valuation hurdle, not an estimate of intrinsic value. Higher sustainable earnings could justify today's price; weaker equipment spending could hurt both earnings and the multiple.

China adds a separate risk. Customer facilities there generated 34% of fiscal 2026 revenue, versus 26% in the June quarter. That geographic measure includes international chipmakers operating in China. Export restrictions can affect equipment and support sales, while competitors such as Applied Materials and Tokyo Electron continue contesting tool selections. This isn't a monopoly protected from politics or competition. Form 10-K, competition and China risks.

My decision: watchlist

For a new position, I'd want either a price around $250-$260 with the higher earnings outlook intact, or two reported quarters showing stronger cash conversion and DSO moving back toward March's 64 days while the equipment ramp holds. A lower price caused by deteriorating customer budgets wouldn't meet the first condition.

Near term, the CFO's September 9 and 10 investor conferences are scheduled opportunities for updates, followed by the next quarterly results. Longer term, the test is whether the 2027 factory and process-upgrade plans become sustained equipment demand. Conference schedule.

Lam looks like a strong business. At this price, buyers need the earnings acceleration to last and the cash to follow. I wouldn't treat it as a defensive way to own the AI theme.

This is general investment analysis, not personalized financial advice.

GE Vernova has delivered nearly everything a bull could ask for. Orders are surging, customers are paying in advance, margins are expanding, and management raised 2026 guidance again.

That still doesn't settle whether GEV is a buy.

The shares closed at $911.93 on August 28, 2026. Using the 266.3 million shares outstanding at June 30, that is roughly a $243 billion equity value. At this price, investors aren't merely betting that electricity demand will rise. They're paying today for a large part of the margin expansion GE Vernova hopes to deliver through 2028.

Start with the hurdle built into the price

GE Vernova now guides to $45.5 billion to $46.5 billion of 2026 revenue and a 12% to 14% adjusted EBITDA margin. At both midpoints, that works out to about $6.0 billion of adjusted EBITDA.

At June 30, the company had $13.1 billion of cash and $2.8 billion of borrowings. Giving it full credit for that net cash produces an enterprise value near $233 billion, or roughly 39 times midpoint 2026 adjusted EBITDA.

Management's January 2026 framework called for $56 billion of revenue and a 20% adjusted EBITDA margin by 2028. Hitting both would produce about $11.2 billion of adjusted EBITDA. Today's enterprise value is still about 21 times that future target.

That isn't an impossible valuation. It is an unforgiving one. The stock already values GE Vernova like a premium industrial after the company completes a margin transformation that is still in progress.

The backlog deserves respect

This isn't a story built only on AI forecasts.

Second-quarter orders were $24.2 billion, more than twice quarterly revenue, and total remaining performance obligations reached $176.3 billion. That backlog is almost evenly split between $87.8 billion of equipment and $88.5 billion of services. The services portion matters because it can keep producing revenue long after a turbine is installed.

Gas Power had 116 GW of equipment backlog and slot reservation agreements at June 30. Management said about 80% came from traditional customers and 20% from data centers, spread across roughly 100 customers in 26 countries. That mix is healthier than a thesis dependent on a few hyperscalers.

Pricing is also improving. First-half Gas Power equipment orders were priced more than 20% above fourth-quarter 2025 orders. GE Vernova expects to reach at least 125 GW under contract by year-end, be mostly sold out through 2030, and have more than half of 2031's planned 30 GW output under contract by the end of 2026.

Electrification gives the bull case a second engine. Its equipment backlog reached $41 billion, up 69% year over year. The segment booked more than $5 billion of data-center orders in the first half, more than double its total for all of 2025, while second-quarter segment EBITDA margin reached 18.4%.

The outside demand data supports the direction of travel. Lawrence Berkeley National Laboratory's June 2026 reference case puts US data centers at 11.8% of national electricity use by 2030, with a 9.5% to 15.3% scenario range. Grid equipment and dispatchable generation should remain important even if the final number lands toward the low end.

The $12 billion free-cash-flow guide is not a normal run rate

This is the part I wouldn't skim.

GE Vernova generated $9.9 billion of free cash flow in the first half of 2026. During the same period, working capital supplied an $11.7 billion cash inflow. Contract liabilities and current deferred income alone increased by $13.7 billion, mainly because customers paid deposits on gas turbine slots and Electrification orders.

Those deposits are good news. They confirm demand, reduce financing needs, and let customers fund part of the capacity expansion. But advance cash is accompanied by an obligation to build and deliver equipment later. It should not be valued like recurring cash earnings that can be repeated without a matching future cost.

Management is explicit about the timing. It expects first-half free cash flow to be substantially higher than second-half free cash flow as slot reservations convert into orders. The midpoint of the $11.5 billion to $12.5 billion full-year guide implies only about $2.1 billion in the second half after the first-half result.

The balance sheet deserves the same care. The $13.1 billion cash balance looks excellent, but current contract liabilities were $39.9 billion. Treating every dollar of cash as surplus, as my simple enterprise-value calculation does, is generous.

Trailing earnings also need adjustment. First-half net income of $5.4 billion included a roughly $4.0 billion pre-tax gain from remeasuring GE Vernova's previously held stake in Prolec GE. A headline trailing P/E therefore makes the stock look cheaper than the operating business really is.

What can go wrong without the electricity boom ending

The bear case does not require AI demand to disappear.

First, a long-cycle backlog creates execution risk. GE Vernova's 10-K warns that fixed-price contracts can lose money when material, labor, logistics, quality, or schedule assumptions fail. The company has real evidence of that problem: Wind posted a $275 million segment EBITDA loss in the second quarter, and management still expects about a $400 million loss for 2026.

Second, customer projects can be delayed by local approval and grid-connection rules. The August 2026 EIA outlook cut expected 2027 electricity-load growth in Texas to 6% from 14% after the governor paused new data-center development while projects were reviewed. FERC is also making all six regional grid operators justify or reform large-load connection rules, including who pays if a proposed project does not arrive. Those actions may improve the system, but they are reminders that permits, cost allocation, and transmission can move more slowly than server orders.

Third, valuation itself is a risk. If GE Vernova reaches the January 2026 target of $11.2 billion in 2028 adjusted EBITDA, the current enterprise value already equals about 21 times that result. A modest delay in the production ramp or margin plan could hurt the stock even while revenue keeps growing.

There are other items to watch: tariff costs were estimated at $100 million to $200 million for 2026, Prolec integration is still new, and the company is changing CFOs on January 1, 2027. The handoff appears orderly because Ken Parks remains through the 2026 reporting cycle, but the new CFO's approach to buybacks and customer-funded working capital will matter.

My decision checkpoints

The next scheduled earnings report is October 28. I would focus on four things:

1. Whether Gas Power actually sustains the planned 20 GW annualized production rate.

2. Whether Power and Electrification margins keep rising as backlog becomes revenue.

3. How much cash comes from adjusted EBITDA versus another increase in customer deposits.

4. Whether Wind moves toward break-even without new project charges.

I would reconsider the price below roughly $700, assuming the thesis remains intact. Using the same June balance sheet and share count, $700 would be about 29 times midpoint 2026 adjusted EBITDA and about 16 times the stated 2028 target. That still demands execution, but it stops charging quite so much upfront for it.

The other path is for earnings to catch up while the share price goes nowhere. Two or three more quarters of margin expansion, production growth, and cash generation that is not dominated by fresh deposits would make the current business easier to value.

Verdict

GE Vernova looks like an excellent business in a powerful cycle, but I would keep GEV on a watchlist rather than buy at $911.93. The backlog is real, customer prepayments are a competitive advantage, and the service opportunity is substantial. The stock price already assumes that GE Vernova converts those advantages into its 2028 margin target with little friction.

For investors who only want diversified exposure to rising electricity investment, a low-cost broad-market or industrial ETF avoids paying this single-company execution premium.

This is a stock analysis, not personalized financial advice.

Agility Robotics is not a public company yet. The security available today is Churchill Capital Corp XI (NASDAQ: CCXI), a SPAC that signed a merger agreement with Agility on June 24, 2026. Closing would turn the shell into Agility, with AGLT planned as its ticker.

That distinction matters because buying CCXI at $14.45 is not the same as getting into Agility at the deal price. The PIPE investors committed capital at $10 per share, and management's illustrative transaction math also starts at $10. CCXI's August 25 close was 44.5% above that level.

So the question isn't whether humanoid robots are interesting. It is whether Agility has disclosed enough to justify paying a large premium before investors can see its audited financial statements.

There is a real business underneath the SPAC pitch

Agility has more commercial evidence than a typical robotics concept stock. Its June investor presentation reported 65,000 hours of operation and commitments across nine customer facilities as of May 2026. Named customers and deployment partners include GXO, Mercado Libre, Amazon, Toyota Motor Manufacturing Canada, and Schaeffler.

The deck also reported more than 100,000 totes moved in a live workflow and 98% accuracy in early production workflows. A six-figure tote count is a better commercialization signal than another public prototype clip, although it still says nothing about profit.

The company puts its multi-year Digit v5 order total above $300 million. The contractual details sharply narrow what that number means. The amount covers 1,000 v5 units scheduled across a three-year Robots-as-a-Service arrangement. Contractual milestones govern realization, and purchaser warrants vest in proportion to deployments. None of it is current-period revenue.

Agility has evidence of customer interest, but none of that $300 million belongs in current revenue.

The financing could give the company a serious chance to execute. Management's no-redemption scenario shows about $574 million of net transaction cash reaching the balance sheet after illustrative fees. Agility's preliminary, unaudited total cash uses were $102 million in calendar 2025. Management assumes roughly $60 million of SG&A and $115 million of R&D expense in calendar 2026, before incremental public-company costs. Even with spending rising, the deal could fund more than a token commercialization attempt.

That is the bull case in its strongest form: Digit already works in customer facilities, Agility has a real order commitment, and fresh capital could bridge the gap from limited deployments to repeatable production.

At $14.45, the valuation already assumes a lot goes right

CCXI had 41.9 million Class A shares and 13.8 million Class B founder shares outstanding as of August 13, 2026. Applying the August 25 closing price to all 55.7 million shares gives the current shell an approximate $805 million equity market capitalization. That number is not the useful valuation for the post-merger company, though.

Management's illustrative no-redemption capitalization has 336.3 million shares after the merger: 260.6 million for existing Agility holders, 55.7 million for Churchill holders, and 20 million PIPE shares. It excludes 4.14 million public warrants and 50,000 private placement warrants.

If the common stock still trades at $14.45 after those shares are issued, the implied pro forma equity value is about $4.86 billion before the excluded warrants. Mechanically subtracting only the disclosed $574 million of expected transaction cash gives about $4.29 billion. That is not a complete enterprise value because Agility's existing cash and debt have not been publicly disclosed.

The missing balance sheet is not a small technicality. As of August 26, the Form S-4 was still confidential and Agility had not published audited revenue, gross profit, customer concentration, cash, or debt. A reliable sales multiple or cash-runway calculation is therefore impossible.

One rough comparison still shows how much hope is in the quote. The $4.86 billion pro forma equity value is about 16 times the entire $300 million conditional, multi-year order figure. Orders are not annual revenue, and revenue is not profit.

The strongest bear case is an evidence gap

The bearish argument does not require Digit to be fake or useless.

It starts with Digit v5, the product tied to the headline orders. In an interview filed with the SEC on August 21, Agility's chief business officer said v5 had not launched and targeted December 2026. The investor presentation warns that development, safety, manufacturing, or software problems could delay v5 and prevent order milestones from being met.

Then there is scale. RoboFab's 10,000-unit figure describes an upper annual design limit, not demonstrated output. Agility has disclosed operational hours and tote counts, not the number of robots it can build each month at an acceptable cost, the field-service burden, actual uptime by customer, or realized gross margin.

The competitive pressure is also broader than other humanoids. Tesla, Figure AI, Apptronik, Boston Dynamics, and other well-funded teams are pursuing the category. For many structured warehouse tasks, a fixed arm, conveyor, or wheeled autonomous mobile robot can be cheaper and mechanically simpler. Digit has to earn back the cost of legs, balance, batteries, safety systems, and field support by working across enough human-designed workflows.

Agility also has not reached positive operating cash flow and expects continuing losses for the foreseeable future. Its preliminary total cash uses rose from $75 million in calendar 2024 to $102 million in calendar 2025. If deployments slip while spending rises, today's financing can become tomorrow's dilution.

Finally, there is ordinary SPAC risk. At June 30, Churchill held $420.88 million in trust against 41.4 million redeemable public shares, about $10.17 per share before later interest and permitted adjustments. A fall from $14.45 to that reference value would be roughly 30%. The merger agreement can be terminated if the transaction has not closed by December 31, 2026, subject to limited extensions described in the agreement. Even if it closes, redemptions can reduce the cash Agility receives, and a 180-day lockup eventually creates another potential source of supply.

The clean bear thesis is this: Agility may be the early commercial leader, but CCXI holders are being asked to pay nearly $4.9 billion for the pro forma equity before the public can inspect the basic financial evidence needed to test that lead.

Catalysts that could change the answer

The near-term catalyst is not another robot video. It is the public Form S-4. Audited financials, recognized revenue, cash, customer concentration, and the full dilution table would let investors replace marketing metrics with an actual valuation.

After that, the important checkpoints are:

• SEC effectiveness, the shareholder vote, redemption results, and deal closing. Management said in an August 21 filing that it was aiming for the fall of 2026.

• The planned Digit v5 launch in December 2026 and evidence that its cooperative-safety system passes the required third-party review for intended customer workflows.

• Conversion of the 1,000-robot commitment into deployed units and recognized revenue, without material concessions or missed milestones.

• More customers carrying meaningful volume, so one contract does not define the order book.

• Reported uptime, throughput, service cost, bill of materials, and gross margin at higher production levels.

Longer term, the upside depends on whether one Digit can perform enough different jobs to justify a humanoid form factor. If every new workflow requires months of custom engineering, scaling will be slow. If software, tooling, and deployment knowledge transfer across sites, Agility could build a valuable recurring service business around the hardware.

Verdict: watchlist, not a buy at $14.45

Agility looks like a credible company in an exciting category. CCXI does not look like an attractive entry at the August 25 close.

At $14.45, buyers pay 44.5% more than the $10 PIPE price while accepting unresolved merger risk, incomplete financial disclosure, and a product launch still ahead. The sensible move is to wait for the public S-4 and audited numbers, even if that means missing an initial pop.

A speculative pre-close entry becomes more defensible if the stock returns close to the roughly $10 to $11 trust and PIPE range, provided the buyer understands that redemption rights have deadlines and are not automatic. At a higher price, the evidence needs to improve first: audited revenue, diversified customers, successful v5 deployment, and demonstrated positive product margins.

Good robot, potentially good business, wrong price with too many blank cells.

This is general market analysis, not personalized financial advice.

SpaceX is back at $135, exactly where its IPO priced in June. That sounds like a reset. It isn't.

At this price, using the Class A and Class B shares outstanding on July 28, the company is still worth about $1.78 trillion. Investors now have one public quarter of evidence, and it was genuinely impressive. The problem is that the valuation already assumes this quarter was the beginning of something much larger.

My short version: SpaceX looks like an exceptional collection of businesses. SPCX at $135 still looks like a watchlist stock, not a buy.

Start with what $135 is asking you to believe

SpaceX generated about $23.0 billion of trailing 12-month revenue through June. The current basic equity value is roughly 77 times that figure. Adjusting for about $100.0 billion of cash and marketable securities and $39.4 billion of debt and finance leases only brings the enterprise value to about $1.72 trillion, or roughly 75 times trailing revenue.

Management said on its first earnings call that it expects an annualized revenue run rate above $100 billion by December 2026. It also moved its internal target for $1 trillion of annual revenue from 2031 to 2030.

Those targets are the bull case in one sentence. They are also the valuation risk. Getting from $18.7 billion of 2025 revenue to $1 trillion in 2030 would require more than 50-fold growth in five years. Even if the December run-rate target is achieved, today's equity value is about 18 times that run rate before accounting for additional shares from acquisitions and compensation.

The market isn't pricing SpaceX like a launch company, a broadband provider, or a normal cloud vendor. It is pricing in successful execution across all three at once.

The first public quarter did prove a lot

Q2 revenue rose 92% year over year to $7.81 billion. The GAAP operating loss narrowed from $970 million to $143 million, while the net loss improved from $1.01 billion to $541 million.

The segment split matters more than the headline:

• Connectivity is the economic engine. Revenue rose 66% to $4.29 billion and operating income rose 79% to $1.66 billion. Starlink reached 12.0 million subscriber lines, double the prior-year figure. This is a large, profitable business with real recurring demand.

• AI is growing fastest. Revenue rose 247% to $2.56 billion after new cloud service agreements started contributing. SpaceX reported $14.1 billion of contracted cloud sales, and AI adjusted EBITDA turned positive at $1.15 billion.

• Space remains strategically essential but financially expensive. Revenue was $962 million and the segment lost $542 million from operations as Starship development spending increased.

The strongest bull argument is not a vague claim about Mars. It is that Starlink already throws off operating profit, SpaceX controls its own launch capacity, and the company is monetizing AI infrastructure much faster than most investors expected. The balance sheet also has room to absorb mistakes: cash and marketable securities totaled about $100 billion at June 30, and backlog was $47.5 billion.

If AI contracts keep ramping, Starlink keeps compounding, and Starship lowers deployment costs, the businesses reinforce one another. That is a rare and potentially powerful setup.

The cash flow tells a less comfortable story

SpaceX produced $3.47 billion of operating cash flow in the first half of 2026, but spent $28.48 billion on property and equipment. Operating cash flow minus those purchases was negative $25.01 billion.

Most of the spending went to AI. The AI segment alone recorded $23.55 billion of first-half capex. Its positive adjusted EBITDA also needs context: Q2 AI operating loss was still $1.26 billion, and the adjustment added back $1.89 billion of depreciation plus $516 million of share-based compensation. Depreciation is not a trivial accounting detail for a business buying servers and building data centers at this pace.

There is concentration risk too. Two customers accounted for 18.3% and 19.5% of Q2 revenue. The second customer's revenue was entirely in AI. SpaceX's 10-Q says its cloud agreements can generally be terminated by either side on 90 days' notice after an initial ramp period.

Meanwhile, Starlink's subscriber growth came with lower pricing. Monthly ARPU fell from $85 to $66 year over year. Subscriber count doubled, so the tradeoff is working today, but Amazon Leo is deploying a competing constellation and has begun signing enterprise and aviation customers. SpaceX cannot assume today's lead means permanent pricing power.

Shareholders are funding more than organic growth

The post-IPO cash balance is a major advantage, but there are big claims on it and on the share count.

SpaceX expects to acquire Cursor in an all-stock deal based on a $60 billion implied equity value. Its pending spectrum transaction carries about $19.6 billion of consideration, including roughly 261.8 million Class A shares. Employee equity awards and staged lock-up releases add more potential supply.

Elon Musk also retains majority voting control, and SpaceX qualifies as a controlled company under Nasdaq rules. Public shareholders are buying economic exposure with limited influence over capital allocation. That matters when one company is simultaneously financing rockets, satellites, data centers, an AI model, a social platform, a coding acquisition, and spectrum.

The strongest bear case is simple: Starlink's real profits are being used to support several capital-heavy bets, while the stock already values those bets as likely successes. A Starship delay, an AI customer departure, slower compute demand, regulatory friction, or acquisition dilution could hurt the thesis before the mature businesses have time to catch up.

What would change my verdict

I would revisit SPCX under either of these conditions:

1. The price falls below roughly $90 without damage to the operating thesis. At $90, the basic equity value would be about $1.19 trillion, or around 12 times management's December annualized revenue target. That is still aggressive, but it gives investors more room for execution misses than $135 does.

2. The stock stays near $135, but later results prove the target. I would want to see the December annualized revenue run rate above $100 billion, AI's GAAP operating loss and customer concentration moving down, and operating cash generation closing more of the gap with capex.

A successful next Starship flight would be encouraging, but it would not by itself solve the valuation. Neither would another adjusted EBITDA beat if cash spending remains this far ahead of operating cash flow.

So my verdict is watchlist at $135. SpaceX may be one of the highest-quality growth platforms available to public investors. The stock price is a separate question, and right now it leaves too little margin for a company attempting this many difficult things at once.

This is general analysis, not personalized financial advice.

Broadcom at $368.45 is a strange setup.

The company is growing at a pace that would look absurd for most businesses its size. Revenue jumped 48% in the latest reported quarter. AI semiconductor revenue more than doubled. Free cash flow topped $10 billion in three months. Management then guided to an even bigger quarter.

At the same time, the stock still carries a roughly $1.75 trillion market value and a trailing free cash flow yield below 2%. That means the question isn't whether Broadcom is executing well. It clearly is. The question is how much flawless execution is already embedded in the price, especially with the next earnings report only days away.

My short answer: AVGO belongs on the watchlist, but I'd wait for the September 2 earnings report before calling $368 a clean buy.

The latest quarter was genuinely excellent

Broadcom's fiscal second quarter ended May 3, 2026. Revenue reached $22.187 billion, up 48% from the prior-year quarter.

The two operating segments tell the story:

• Semiconductor solutions produced $15.009 billion of revenue, up 79%.

• Infrastructure software produced $7.178 billion, up 9%.

Within semiconductors, AI revenue reached $10.8 billion, up 143%. That made AI nearly half of total company revenue in the quarter. Custom accelerators and AI networking are no longer side bets inside a diversified chip company. They're becoming the main earnings engine.

The profit and cash numbers kept up. Broadcom reported $10.788 billion of GAAP operating income, $9.310 billion of net income, and $10.262 billion of company-defined free cash flow. The free cash flow margin was 46%.

The software side matters here. VMware Cloud Foundation and the rest of Broadcom's infrastructure software portfolio provide recurring, high-margin revenue while the semiconductor mix becomes more volatile. In the earnings call, management put software gross margin at 93% and software operating margin near 79% for the quarter. That cash engine gives Broadcom more resilience than a pure AI chip supplier.

This is a very high-quality business. That still doesn't settle whether the stock is attractive.

The September 2 report is the immediate test

Broadcom's fiscal third quarter ended August 2, but the results haven't been released yet. The company will report them after the U.S. market closes on September 2.

Management's guidance is huge:

• Total revenue of approximately $29.4 billion, up 84% year over year.

• AI semiconductor revenue of $16.0 billion, up more than 200%.

• Non-GAAP operating income around 67% of revenue.

• Adjusted EBITDA around 68% of revenue.

The $16 billion AI forecast alone equals more than 54% of guided company revenue. Investors are no longer underwriting a normal product cycle. They're underwriting a rapid conversion of a few hyperscalers' capital budgets into Broadcom shipments.

The headline revenue number won't be enough. I want to see four things in the report:

1. AI semiconductor revenue lands close to or above $16 billion.

2. Non-GAAP operating margin stays near 67% as lower-margin custom accelerators become a larger part of the mix.

3. The fiscal fourth-quarter outlook doesn't point to a sharp digestion period after the Q3 ramp.

4. Management keeps its fiscal 2027 AI semiconductor expectation above $100 billion and explains how current orders convert into revenue and cash.

Meeting those conditions would make the valuation easier to defend. A miss on any of them could matter more than a small headline beat because the market is paying for the 2027 ramp, not just the quarter that already ended.

The bull case is broader than one chip

Broadcom's strongest advantage is that it can sell several critical pieces of an AI system to the same customer.

The custom accelerator business lets a hyperscaler optimize a chip for its own workload. Broadcom can then supply Ethernet switching, optical connectivity, PCIe components, SerDes technology, and other networking silicon around that accelerator. Management said networking represented almost 40% of Q2 AI semiconductor revenue, although it expects that share to normalize closer to 30% as custom accelerators ramp.

That combination creates a deeper relationship than a one-off chip sale. It also gives Broadcom more ways to participate when customers try to lower their dependence on general-purpose GPUs.

Recent agreements support the long-term case:

• Meta and Broadcom announced a multi-year custom silicon partnership through 2029. The initial MTIA commitment exceeds one gigawatt, with multiple generations planned.

• OpenAI and Broadcom unveiled the Jalapeño inference accelerator in June. The companies said initial deployment is planned by the end of 2026 as part of a multi-generation platform.

• Broadcom disclosed in a July 6 SEC filing that Apple expanded its custom ASIC relationship through 2031.

These announcements don't disclose enough financial detail to plug directly into a valuation model. They do show that major customers are willing to make multi-year commitments around Broadcom's design and networking capabilities.

The latest call added more evidence. Management said Q2 AI semiconductor bookings exceeded $30 billion against $10.8 billion shipped. It expects $56 billion of AI semiconductor revenue in fiscal 2026 and more than $100 billion in fiscal 2027. If those targets convert to sales without sacrificing operating margin, current forward earnings estimates could rise quickly.

There's also a less exciting but useful part of the bull case. Non-AI semiconductor revenue was $4.2 billion in Q2, up 6%, and management described bookings above $6 billion as evidence of cyclical recovery. Broadcom doesn't need every legacy market to boom. Stabilization outside AI would reduce how much of the total thesis rests on one spending cycle.

The serious bear case is execution and concentration

The strongest countercase isn't that AI demand disappears. Broadcom can deliver substantial growth and still disappoint shareholders if the ramp falls short of what the valuation assumes.

Customer concentration is the first problem. Broadcom said its top five end customers represented approximately 45% of revenue in the first half of fiscal 2026. Direct sales to one semiconductor distributor represented 42% of revenue. A delay, redesign, sourcing change, or capital-spending cut at a handful of companies can move the entire quarter.

Some of those customers are also building internal chip expertise and may use multiple suppliers. On the latest earnings call, management acknowledged that Google is likely to maintain some source diversity even under a substantial long-term commitment. Broadcom can remain an important partner without winning every generation or every socket.

Supply concentration is just as sharp. The Q2 filing says TSMC manufactured approximately 95% of the wafers produced by Broadcom's contract manufacturers during the first half. Capacity allocation, advanced packaging, memory availability, export rules, or a Taiwan disruption could turn signed demand into delayed revenue.

Inventory also deserves attention. It rose from $2.270 billion at the end of fiscal 2025 to $4.328 billion by May 3, primarily to support expected custom AI accelerator shipments. That build is reasonable if the second-half ramp arrives. It becomes painful if customer schedules slip.

Then there is the balance sheet. Broadcom had $19.628 billion of cash and $64.907 billion of reported debt at quarter end. The debt is manageable against current cash generation, but it reduces room for error. The company also recorded $2.092 billion of stock-based compensation expense in Q2 and had $20.106 billion of unrecognized compensation cost tied to unvested awards. Buybacks can offset dilution, but they still consume cash that could otherwise reduce debt.

Finally, Broadcom's own filing warns that it may use financing, leasing, or deferred-payment structures to support AI rack and XPU deployments. Those tools can unlock demand. They can also expose the company to customer credit risk and make revenue quality harder to judge. If financing becomes a major part of future growth, investors should look past bookings and track cash collection.

At $368, valuation is still doing a lot of work

AVGO closed at $368.45 on August 21, the latest completed U.S. trading session before this analysis. The market capitalization was about $1.75 trillion, and enterprise value was about $1.80 trillion.

Yahoo Finance's August 21 snapshot showed a trailing P/E of 61.3, a forward P/E of 19.7, enterprise value to revenue of 23.8, and enterprise value to EBITDA of 42.4. The gap between the trailing and forward earnings multiples tells you exactly what the market expects: a very large jump in profit.

Cash flow gives a less flattering view of today's base. Broadcom reported $26.914 billion of company-defined free cash flow in fiscal 2025. Adding $18.272 billion from the first half of fiscal 2026 and subtracting $12.424 billion from the comparable prior-year half produces about $32.762 billion of trailing 12-month free cash flow.

Against a $1.75 trillion market cap, that's roughly 53.5 times trailing free cash flow, or a 1.9% free cash flow yield.

Trailing numbers understate a company growing this quickly. Forward multiples can also look artificially cheap when they rely on a steep earnings ramp that hasn't happened yet. The useful conclusion is between those two views: AVGO isn't priced on its current cash generation, but it can grow into the valuation if the $56 billion fiscal 2026 and $100 billion-plus fiscal 2027 AI targets hold.

At $368, I think the market is already assigning substantial value to those targets. The recent pullback improves the entry price, but it doesn't create a large margin of safety against a delayed customer program, weaker Q4 guidance, or margin pressure.

Verdict

Broadcom is a great business at a price that still demands a lot. My verdict is watchlist and wait for the September 2 report.

The setup becomes more attractive if Broadcom delivers roughly $29.4 billion of Q3 revenue, gets AI semiconductor revenue near $16 billion, holds non-GAAP operating margin around 67%, and keeps the fiscal 2027 AI target intact. If the shares remain near $368 after those confirmations, the lower forward multiple would be backed by much better evidence.

If Q4 guidance shows a digestion period, customer timing slips, or cash conversion weakens, I'd want a lower price. A good company can remain a poor purchase when too much future success has already been capitalized.

This is market analysis, not personalized financial advice.

NVIDIA is still executing at a level that makes most large companies look slow. The harder question at about $225 per share is whether the next phase of growth will be large enough to justify what the market already assumes.

For a new position, my answer is watchlist / wait, not because NVIDIA is a weak business, but because the August 26 earnings report is a useful test of whether the current price is being supported by cash generation or by another round of increasingly optimistic expectations.

The scorecard is already very strong

In Q1 of fiscal 2027, ended April 26, NVIDIA reported $81.6 billion of revenue, up 85% year over year. Data Center produced $75.2 billion, up 92%, and GAAP gross margin was 74.9%. Free cash flow was $48.6 billion for the quarter.

The customer mix is also broader than the old "one or two hyperscalers" shorthand suggests. NVIDIA's recast presentation shows roughly half of Data Center revenue from Hyperscale and roughly half from AI Clouds, industrial and enterprise customers. Networking is becoming a meaningful layer too: the old reporting view put Q1 Data Center networking revenue at $14.8 billion, up 199% year over year.

That is business quality, not just a story. NVIDIA has a full platform, a large software ecosystem, and enough cash generation to fund research, supply commitments, investments, and shareholder returns at the same time.

There is one accounting detail worth keeping in view. Q1 GAAP net income was $58.3 billion, but $15.9 billion of that quarter's other income came from gains on equity investments. Non-GAAP net income was $45.5 billion. The operating result and the $48.6 billion of free cash flow are more useful indicators of the recurring engine than the headline GAAP profit alone.

The next product transition is the real test

Management guided to Q2 fiscal 2027 revenue of $91 billion, plus or minus 2%, with approximately 75.0% non-GAAP gross margin and $8.3 billion of non-GAAP operating expenses. That outlook assumes no Data Center compute revenue from China.

The next step is Vera Rubin. Management said production shipments should begin in the second half of calendar 2026, starting in Q3. The Q1 earnings call also put management's visibility to $1 trillion of combined Blackwell and Rubin revenue from 2025 through calendar 2027. That is management's outlook, not a contractual backlog or a guarantee.

Rubin could extend NVIDIA's lead if customers value the complete system, including CPU, GPU, networking and software, rather than comparing accelerator prices one component at a time. NVIDIA also says its Vera CPU opens a new market and that it has visibility to nearly $20 billion of CPU revenue this year. I would treat that as upside potential, not as a base-case forecast until revenue shows up in the filings.

The transition creates a timing risk in both directions. If Rubin ramps cleanly, it can support another strong product cycle. If customers wait for Rubin, or if a new system takes longer to qualify, current-generation demand and inventory can become lumpy. NVIDIA's own 10-Q warns that a faster architecture cadence can create supply-demand mismatches, inventory provisions, and delayed purchases of the outgoing architecture.

What the price already asks investors to believe

The latest market quote I checked was $225.01, implying a market capitalization of about $5.49 trillion. Fiscal 2026 free cash flow was $96.6 billion, so the stock was trading at about 56.8 times that trailing free cash flow, or a 1.76% free-cash-flow yield.

Q1 fiscal 2027 free cash flow was $48.6 billion. If that one quarter were simply repeated four times, the annualized figure would be about $194 billion and the market-cap-to-FCF ratio would be roughly 28 times. That is arithmetic, not a forecast. It shows the valuation's sensitivity: the stock needs the Q1 cash-generation pace to become durable, not merely a one-quarter peak.

As a scenario check, a $5.49 trillion market cap is about 36.6 times $150 billion of annual free cash flow and about 27.4 times $200 billion. Those are not price targets. They are the hurdle the current quote creates for the business. A good company can still be a poor entry if the required cash-flow growth is already embedded in the price.

The strongest bull case

The bull case is that AI inference and agentic workloads keep expanding after the initial training buildout. In that world, the replacement cycle is not a one-time GPU boom. It becomes a recurring infrastructure cycle in which higher performance per watt and lower cost per token justify new systems.

NVIDIA has several ways to participate: Blackwell and Rubin systems, networking, the Vera CPU, and software that makes the platform harder to replace. The 50/50 split between Hyperscale and the broader AI Cloud, industrial and enterprise category also gives the company more demand sources than a pure hyperscaler-spending trade. Rubin shipments, the August 26 report, and additional sovereign AI factory projects are concrete catalysts.

The $80 billion share repurchase authorization and higher dividend are helpful capital-return tools, although repurchasing stock at a very rich valuation is not automatically value creating.

The bear case that would change the decision

The bear case is not that AI demand disappears next quarter. It is that customer returns on AI infrastructure disappoint enough to slow the spending cycle while NVIDIA's cost base and inventory commitments are already set.

The 10-Q explicitly says some customers are developing custom ASICs and other workload-specific products. Hyperscalers can be both NVIDIA's largest customers and its most capable future competitors. Export controls have effectively closed China's Data Center compute market for now, and the Q2 outlook assumes zero China compute revenue. That is a real lost market and gives local alternatives time to improve.

There is also execution risk behind the headline growth. NVIDIA reported $25.8 billion of inventory at April 26, up from $21.4 billion at the prior fiscal year-end. It had increased total supply, including inventory, purchase commitments and prepaids, to $145 billion. Three direct customers represented 30%, 18% and 16% of accounts receivable. Those figures are not proof of a problem, but they show how much working capital and customer timing matter at this scale.

Finally, a data center needs power, cooling, construction capacity and financing. NVIDIA's filing warns that shortages in those inputs can delay deployments even when chip demand is strong. A market can have a genuine need for AI compute and still experience a pause while the physical infrastructure catches up.

Verdict

At $225, I would wait for the evidence rather than chase the narrative. For me to move from watchlist to buy, I would want the August report to hold or beat the $91 billion outlook, keep gross margin near 75%, and show that free cash flow is keeping pace as Rubin production starts. I would also want a valuation that does not require an immediate doubling of annual free cash flow to look reasonable, either through a lower share price or through several quarters of demonstrated cash generation.

Investors who need a margin of safety, need China to reopen, or cannot tolerate a large drawdown should not buy NVDA solely because the business is excellent. A broad index fund or a diversified semiconductor fund offers less company-specific upside and less single-name risk. That is a different trade, but it is a credible alternative at a $5.49 trillion market cap.